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INTRODUCTION 
 
  
1.0 INTRODUCTION: 
 
The oral route of drug administration is the most important method of 
administering drugs for systemic effects. Of drugs that are administered orally, solid 
oral dosage form represents the preferred class of products.  
 Solid medicaments may be administered orally as powders, pills, cachets, 
capsules or tablets. These dosage forms contain a quantity of drug which is given as 
a single unit and they are known as solid unit dosage forms. Tablets represent unit 
dosage form in which one usual dose of the drug has been accurately placed.
1 
 
Tablet may be defined as solid pharmaceutical dosage forms containing drug 
substance with or without suitable diluents and have been traditionally prepared 
either by compression or molding methods. 
 Frequently, tablets are discoid in shape; they are also round, oval, oblong, 
cylindrical or triangular. They differ greatly in size and weight depending on the 
amount of drug substance present and intended method of administration.
2 
Tables are obtained by compression of uniform volumes of powders 
or granules by applying high pressure and using punches and dies. The particles to 
be compressed consist of one or more medicaments, with or without auxiliary 
substance such as diluents, binders, and disintegration agents, lubricant, glide ants 
and substances capable of modifying the behaviour of the medicaments in the 
digestive tracts. Such substances must be innocuous and therapeutically inert in the 
quantities present. 
Due to emergence of precompression, induced die feeding, high -speed, 
ultrahigh-speed presses, automated weight-control systems, the availability of many 
new direct compression materials, and the microprocessor control of 
precompression, compression and  ejection forces  the formulation of solid oral 
dosage forms, especially tablets has undergone rapid changes and development.
3
 
 
 
 
  
1.1 PROPERTIES OF TABLETS
4
:  
The characteristics of an acceptable tablet are as follows: 
1. The hardness and friability tests are the two tests that are conducted in order 
to understand the strength and resistance of the tablet which determine the 
strength towards shock and abrasion which may occur during manufacturing, 
packing, shipping and use.  
2. The drug content and weight of the tablets should be uniform individually. 
The weight variation test and the content uniformity test are performed to 
attain this consistency. 
3. The drug content of the tablet must be bioavailable. This property is also 
measured by two tests, the disintegration test and the dissolution test. 
However, bioavailability of a drug from a tablet, or other dosage form, is a 
very complex problem and the results of these two tests do not provide an 
index of bioavailability. This must be done by blood levels of the drug. 
4. Tablets must be aesthetic in appearance and must have the featured shape, 
colour, and other shape necessities to identify the product. The monogram or 
logo of the manufacturer is a must. 
5. Tablets must retain all of their function, which include drug stability and 
efficacy. 
 
 1.2 The advantages of the Tablet dosage form
5
: 
1. They co me in s ing le  u n it s .  
2. They offer the greatest capabilities of all oral dosage form for the best dose 
precision. 
3. Of all oral dosage forms, Cost is the lowest. 
4. Lighter and compact. 
5. Easiest and cheapest to be packed as strips. 
6. Easy to swallow. 
7. Enteric coating helps in delayed release. 
8. Coating technique can be used to prevent objectionable odor and bitter taste. 
9. Large scale production is easy. 
  
10. Best chemical and microbial stability over all oral dosage form. 
11. Monogrammed punch helps in easy product ident ificat ion requiring no 
additional steps. 
1.3 Disadvantages of tablet dosage form
6
: 
1. Children and unconscious patients feel it hard to take. 
2. Drugs with poor wetting, slow dissolution properties, optimum absorption 
high in GIT may be difficult to formulate or manufacture as a tablet that will 
still provide adequate or full drug bioavailability. 
3. Some drugs resist compression into dense compacts, owing to amorphous 
nature, low density character. 
4. Bitter and objectionable odor tablets are hard to intake which may require 
coating techniques which in turn reflect in the cost of the tablets making it 
costly. 
 
1.4 Oral Drug Delivery
7
: 
Oral drug delivery systems are divided into 3 categories, based on the desired 
therapeutic objectives. 
I. Immediate-release preparations, 
II. Controlled-release preparations and 
III. Targeted- release preparations. 
1.4.1 Immediate-Release Preparations 
These preparations are intended primarily to achieve faster onset of action 
Advantages of immediate release preparations include  
 Enhanced oral bioavailability through transmucosal delivery and pregastric 
absorption 
 Convenience in drug administration to dysphasic patients. 
Conventional IR formulations include granules and fast disintegrating tablets 
that use effervescent mixtures, such as sodium carbonate sodium bicarbonate, citric 
  
acid, tartaric acid and superdisintegrants such as sodium starch glycolate, 
croscarmellose sodium, and crospovidone.  
In fast-dispersing dosage forms, current technologies include modified 
tableting systems, floss or Shear form technology. They employ application of 
controlled temperature, freeze-drying and centrifugal force. 
1.4.2 Controlled-Release Preparations: 
The current controlled release technologies for oral drug delivery include 
diffusion-controlled systems; solvent activated systems, and chemically controlled 
systems. Diffusion-controlled systems are monolithic and reservoir devices. In this 
diffusion of the drug is the rate-limiting step, through a polymer matrix or a 
polymeric membrane. Solvent-activated systems may be either osmotically 
controlled or controlled by swelling of polymer. 
Release of drugs from chemically controlled systems is through degradation 
of polymer (surface or bulk matrix erosion) or cleavage of drug from a polymer 
chain. Programmed-release (‘‘tailored-release’’) profile of a final CR product is the 
outcome of a single pharmaceutical principle. Depending on the specific 
physicochemical properties of the drug and desired therapeutic objectives, different 
formulation and CR principles may be proportionally combined within the same 
dosage form. In terms of appropriate selection of polymers and excipients that 
incorporate desired principles, makes it simple. 
1.4.3 Targeted-Release Preparations: 
Site-specific release oral drug delivery requires spatial placement of a drug 
delivery device at a desired site within the GI tract. Though it is possible to localize 
a device within each part of GI tract, the attainment of site-specific delivery in the 
oral cavity and the rectum is easy compared to that in the stomach and the small and 
large intestines. Consideration of both longitudinal and transverse aspects of GI 
constraints is necessary for small, large intestine and stomach. 
1.5 Stages in manufacturing of tablets
8
: 
Tablets are manufactured by forcing powder particles into close proximity to 
each other by powder compression. This enables the particles to cohere into a 
  
porous, solid specimen of defined geometry. The compression takes place in a die 
by the action of two punches, 
 The lower and  
 The upper, by which the compressive force is applied. 
Powder compression is defined as the reduction in volume of the powder owing 
to the application of the force.  Increased proximity of the particle surface is 
accomplished during compression because of which bonds are formed between the 
particles. This provide coherence to the powder, a compact is formed. Compaction is 
defined as the formation of a solid mass of defined geometry by powder 
compression. 
The process of tableting is divided into three stages. 
1.5.1 Die-filling:  
This step involves the gravitational flow of the powder from a hopper 
through the die table into the die. The die is closed at its lower end by the lower 
punch. 
1.5.2 Tablet formation: 
The upper punch descends down and enters the die. The powder is then 
compressed until a tablet is formed.  The lower punch can be a stationary or can 
move upwards in the die during the compression phase. After application of 
maximum force, the upper punch leaves the powder and ascends up, which is the 
decompression phase. 
1.5.3 Tablet ejection: 
During this phase, the lower punch rises up until its up reaches the level of 
the top of the die. The tablet is subsequently removed from the die subsequently.  
 
 
 
 
 
  
1.6 TYPES OF TABLET MANUFACTURING
9
: 
The tablet manufacturing process can be broadly classified as 
 Granulation 
 Direct compression 
  
 
Figure 1: Tablet manufacturing processes 
  
1.6.1 Granulation: 
1.6.1.1 Wet granulation: 
For powders which are very fine, fluffy, will not stay blended, or will not 
compress, granulation is preferred. Wet granulation involves addition of solution to 
blended powder and mixing is done at a predetermined period of time and at 
specified speed. After this process is complete, the wet mass is milled and dried on a 
tray drier on to which the mass is spread. 
 
1.6.1.2 Dry granulation: 
Dry granulation (roll compaction or slugging) involves the compaction of 
powders at high pressures into large, often poorly formed tablets or compacts. These 
compacts are then milled and screened to form a granulation of the desired particle 
size. The advantage of dry granulation is the elimination of heat and moisture in the 
processing. Dry granulations can be produced by extruding powders between 
hydraulically-operated rollers to produce thin cakes that are subsequently screened 
or milled to give the desired granule size. 
1.6.2 Direct compression: 
Direct compression is used when a group of ingredients are to be blended 
and placed onto a tablet press to be made into a perfect tablet without changing any 
of the ingredients. Powders that can be blended and compressed are commonly 
referred to as directly compressible or as direct-blend formulations.  
 The physical properties of the individual filler materials are highly critical, 
and minor variations in properties can alter flow and compression characteristics 
which make them unsuitable for direct compression.  
The most widely used direct compression fillers include cellulose derivatives 
(e.g. microcrystalline cellulose), saccharides (e.g. lactose and mannitol), mineral 
salts (e.g. Dicalcium phosphate, calcium carbonate) and partially pregelatinized 
starch. 
 
 
 
 
  
TABLE 1: Advantages and Disadvantages of methods of manufacturing. 
 
 
1.7 TYPES OF TABLETS
10
: 
The various types of tablets include, 
1. Compressed tablet 
2. Sugar coated tablet 
3. Film coated tablet 
4. Enteric coated tablet 
5. Multi compressed tablet 
Method Advantage Disadvantages  
Direct 
compression 
 It is Simple, economical 
process 
 No heat or moisture is 
associated, so good for 
unstable compounds. 
 It is not suitable for all kinds of API 
 It is  generally limited to lower dose 
compounds, Segregation potential, 
expensive excipients 
Wet Granulation  It is a robust process 
 It reduce elasticity 
problems and wettablity, 
 Reduced segregation 
potential. 
 It is an expensive process,  
 It is time and energy consuming, 
 Specialized equipments are required 
  Stability issues. 
Wet 
Granulation(Non 
Aqueous) 
 Because of the Vacuum 
drying technique, it is  
suitable for moisture 
sensitive API  
 Expensive equipment,  
 solvent recovery issues,  
 Needs organic facility, health and 
environmental issues. 
Dry Granulation  It eliminates exposure to 
moisture and drying 
 Dusty procedure,  
 slow process,  
 not applicable for all API 
  
1.7.1 Compressed tablet:  
These tablets are formed by compression and they do not have any coating. 
They are made from powdered, crystalline or granular materials alone or in 
combination with binders, disintegrants, controlled release polymers, lubricants, 
diluents and colorants. 
1.7.2 Sugar coated tablets: 
 These are compressed tablets surrounded by sugar coating. Coating may be 
colored and used in covering drug substances possessing objectionable color and 
odor. 
1.7.3 Film coated tablets:  
These are compressed tablets covered with a thin layer or film of a water 
soluble material. Polymers with film forming properties are used. It shows the same 
characters as that of sugar coated tablets. It has an advantage of reduced time period 
for coating. 
1.7.4 Enteric coated tablets:  
These are compressed tablets coated with substances that resist solution in 
gastric fluid but disintegrate in intestine. This coating is used for tablet containing 
drug substances that are inactivated or destroyed in stomach, those that irritate the 
mucosa, or as a means of delayed release of medication. 
1.7.5 Multi compressed tablets:  
These are compressed tablets made by more than one compression cycle. 
This is used when separation of active ingredient is needed for stability purpose or if 
the mixing process is inadequate to guarantee uniform distribution of two or more 
active ingredients. 
1.8 FILM COATING OF SOLID DOSAGE FORMS
11
: 
Film coating is a process that involves deposition of thin, uniform film onto the 
surface of the substrate. Unlike sugar coating, this is a very flexible process that 
allows a broad range of products like tablets, granules, non pareils, and capsules to 
be coated. Film coating are applied continuous to a moving mass of product, usually 
by means of a spray technique, all though manual application procedures have been 
used.  
  
Advantages of film coating include: 
a) Minimal weight increase (typically 2%-3% tablet core weight) 
b) Significant reduction in processing times 
c) Increased process efficiency and output 
d) Increased flexibility in formulations  
e) Improved resistance to chipping of the coating  
 
Figure 2: schematic representation of film coating process 
 
 
Raw materials used in film coating: 
The major component in any film coating formulation consists of polymer, 
plasticizer, colorant and solvent. Ideal properties for the polymer include solubility 
in a wide range of solvent systems to promote flexibility in formulation , an ability 
to produce coating that have suitable mechanical properties and appropriate 
solubility in gastrointestinal fluids such that drug bioavailability is not 
compromised. 
 Cellulose ethers are often the preferred polymers in film coating, particularly 
hydroxyl propyl methyl cellulose. Suitable substitutes include hydroxyl propyl 
  
cellulose, which may produce slightly tackier coatings and methyl cellulose which 
retard drug dissolution. 
1.9 EXCIPIENTS USED IN FORMULATION12: 
  Oral conventional dosage form contains some components other  than active 
pharmaceutical ingredients which are functioning as diluents, binder or adhesive, 
disintegrant, lubricant, colorants, flavors and sweeteners. 
1.9.1 Diluents: 
These are the fillers used to make up the bulk of the tablet when the drug dosage 
form is insufficient to produce the bulk. In some drugs, the dose is high such that no 
filler is required. 
Diluents and other excipients must meet the following criteria: 
 They must be nontoxic and acceptable to the regulatory agencies in all 
countries where the product is to be marketed. 
 Cost must be acceptably low. 
 They should not be contraindicated by themselves. 
 They should be commercially available in all countries where the product is 
to be manufactured. 
 They must be inert physiologically inert. 
 They must be stable physically and chemically by themselves and in 
combination with the drug and other tablet components. 
 They must be color compatible. 
 They must be free of any unacceptable microbiologic load. 
 They should not have any deleterious effect on the bioavailability of the 
drug in the product. 
 If the drug product is also classified as food, the diluents and other 
excipients must be approved direct food additives. 
1.9.2 Binders and Adhesives: 
These materials are added either dry or in a liquid form during wet 
granulation to form granules or to promote cohesive compacts for directly 
compressed tablets. Acacia and tragacanth are natural gums and are employed in 
  
solutions ranging from 10-25% concentration, above or in combination. These 
materials are much more effective when they are added as solutions in the 
preparation of granulations than when they are added dry to a direct compression 
formula. When these materials are used, their wet granulation masses should be 
quickly dried at a temperature above 37
0
c to reduce microbial proliferation. 
1.9.3 Disintegrants
13, 14
: 
A disintegrant is added to most tablet formulations to facilitate a break up or 
disintegrants may function by drawing water into the tablet, swelling and causing 
the tablet to burst apart;. Such tablet fragmentation may be critical to the subsequent 
dissolution of the drugs and to the attainment of satisfactory drug bioavailability. 
Starch USP and various starch derivatives are the most common disintegrating 
agents. They also have the lowest cost. Starch is typically used in a concentration 
range of 5 to 20% of tablet weight Such modified starches as primogel and explotab, 
which are low substituted carboxy methyl starches are used in lower concentration(1 
to 85, with 4% usually reported as optimum). Various pregelatinized starches are 
also employed as disintegrants, usually in a 5% concentration. 
1.9.4 Superdisintegrants
14, 15
: 
When the tablet is taken orally they must dissolve easily so generally 
disintegrating agents are added. Moisture penetration and dispersion of the tablet 
matrix are there major features. In the near years several newer agents have been 
developed known as Super-disintegrants. These super disintegrants are more 
effective at lower concentrations with greater disintegrating efficiency and 
mechanical strength. When these come in contact with water they swell, hydrate, 
change volume or form and produce a disruptive change in the tablet. Good 
superdisintegrants provide improved compressibility, compatibility and have no 
negative impact on the mechanical strength of formulations containing high-dose 
drugs. Disintegrants widely used in tablet manufacturing include: 
Modified starches  
Sodium starch glycolate is the sodium salt of a carboxy methyl ether of 
starch. Its concentration is effective at the range of 2-8%.  High disintegration of the 
tablets is attained by them since they absorb 20 times its weight by which the 
  
swelling capacity is made high. They are available in various grades i.e. Type A, B 
and C, which differ in pH, viscosity and sodium content. Other special grades are 
available which are prepared with different solvents and thus the product has a low 
moisture (<2%) and solvent content (<1%), thereby being useful for improving the 
stability of certain drugs. 
Modified celluloses Carboxy methylcellulose and its derivative (Croscarmellose 
Sodium)  
Cross-linked sodium carboxy methylcellulose is a white, free flowing 
powder with high absorption capacity. They have a high absorbing capacity and so 
they provide rapid disintegration and drug dissolution at lower levels. They have 
great water wicking capability and its cross-linked chemical structure creates an 
insoluble hydrophilic, highly absorbent material resulting ineffective swelling 
properties. Its recommended concentration is 0.5 to 2.0%, which can be used up to 
5.0%. L-HPC (Low substituted hydroxy propyl cellulose) they are insoluble in 
water, swells rapidly and is used in the range of 1-5%. The grades LH- 11 and LH-
21 exhibit the highest degree of swelling. 
Cross-linked polyvinyl pyrrolidone  
They are polymers that are insoluble. As in water they swell like others but 
they do not mix even after a long period of time. There rate of swelling is highest 
among all the superdisintegrants and is effective at 1-3%. There action is determined 
by wicking, swelling and possibly some deformation recovery. These polymers have 
a small particle size distribution that imparts a smooth mouth feel to dissolve 
quickly. Various grades are available commercially according to their particle size in 
order to achieve a uniform spreading for direct compression with the preparation. 
 
 
 
 
 
  
TABLE 2: Mechanism and Concentration of Various Disintegrants 
Disintegrants Mechanism 
 
Concentration 
(%) 
 
Starch 
These disintegrate, forms pathway throughout the tablet matrix. 
This enables the structure to draw water by capillary action 
leading to disruption of tablet 
 
5-20% 
 
Sodium starch 
glycolate 
This involves absorption of water rapidly, which leads to drastic 
increase in volume of granules which result in uniform and rapid 
disintegration. 
 
1-3 
Pregelatinised 
starch 
This is responsible for enhanced dissolution rate. Its rapid 
disintegration is due to superior swelling property. 
 
5-15 
Micro crystalline 
cellulose 
They swell on contact with water resulting in rapid 
disintegration. 
10-20 
Crospovidone This has capillary activity for water resulting in disintegration 
property of tablet. 
1-3 
1.9.5 Lubricants, Anti-adherents and Glidants
16
: 
These three classes of materials are typically described together because they 
have overlapping functions. A material that is primarily described as an anti-
adherent is typically also a lubricant, with some glidant properties as well.  
 Lubricants are intended to reduce the friction during tablet ejection between 
the walls of the die cavity in which the tablet was formed. Anti-adherents have the 
purpose of reducing sticking or adhesion of any of the tablet granulation or powder 
to the faces of the punches or to the die wall. Glidants are intended to promote flow 
of the tablet granulation or powder materials by reducing friction between the 
particles. 
1.9.6 Colors, flavors and sweeteners: 
The use of colors and dyes in tablet making has served three purposes over 
the years: disguising of off-color drugs, product identification, and production of a 
more elegant product. 
  
The availability of natural vegetable colors is limited and these colors are 
often unstable. Two forms of color have typically been used in tablet preparation. 
These are the FD&C and D&C dyes- which are applied as solutions, typically in the 
granulating agent- and the lake forms of these dyes. Lakes are dyes that have been 
absorbed on a hydrous oxide and usually are employed as dry powders for coloring. 
Flavors are usually limited to chewable tablets or other tablets intended to 
dissolve in the mouth. In general, flavors that are water-soluble have found little 
acceptance in tablet making because of their poor stability. Flavor oils are added to 
tablet granulations in solvents, are dispersed on clays and other absorbents, or are 
emulsified in aqueous granulating agents. Various dry flavors for use in 
pharmaceutical products are also available from flavor suppliers.  
 The use of sweeteners is primarily limited to chewable tablet to exclude or 
limit the use of sugar in the tablets. Mannitol is reportedly about 72% as sweet as 
sucrose. Saccharin was the only artificial sweetener available. This material is about 
500 times sweeter than sucrose. Its major disadvantages are that it has a bitter 
aftertaste and has reported to be carcinogenic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3: Common Tablet Excipients: 
 
DILUENTS 
Lactose USP 
Lactose USP, spray dried 
Lactose USP, anhydrous 
Micro crystalline cellulose 
Other cellulose derivatives 
Hydrolyzed starches 
Dextrose 
Sorbitol 
Sucrose USP powder 
Sucrose based material 
BINDERS AND ADHESIVES 
Acacia 
Cellulose derivatives 
Gelatin 
Starch, paste 
Starch, pregelatinised 
 
sorbitol 
 
sodium alginate 
 
Tragacanth 
DISINTEGRANTS 
Starch 
Cellulose 
Starch derivatives 
Alginates 
PVP cross linked 
clays 
LUBRICANTS 
Stearic acid 
Stearic acid derivatives 
Stearic acid salts 
Talc 
Polyethylene glycols 
 
surfactants 
 
waxes 
GLIDANTS AND FLOW PROMOTERS 
Silica derivatives 
Corn starch 
Corn starch 
 
 
COLOURS, FLAVOURS AND DERIVATIVES 
FD&C and D&C dyes and lakes, 
Spray-dried and other flavors,. 
Natural sweeteners 
 
                   Artificial sweeteners 
 
  
1.10 Hypertension
17
: 
Hypertension, high blood pressure, arterial hypertension, is 
a chronic medical condition in which the blood pressure in the arteries is increased 
which requires the heart to work harder than normal. This is to circulate blood 
through the blood vessels. Blood pressure is measured by systolic and diastolic 
pressure, systolic is measured when the heart muscle is contracting and diastolic is 
measured when the heart muscle is relaxed between beats. 
At Normal blood pressure, systolic range is 100-140mmHg (top reading) and 
diastolic is 60-90mmHg diastolic (bottom reading). Blood pressure is said to be high 
if it is persistently at or above 140/90 mmHg. 
Hypertension is classified as either primary hypertension or secondary 
hypertension. Primary hypertension means high blood pressure with no obvious 
underlying medical cause where as secondary hypertension is caused by conditions 
that affect the kidneys, arteries, heart or endocrine system. 
Hypertension is a major risk factor for stroke, myocardial infarction, heart 
failure, aneurysms, peripheral arterial disease. It also causes chronic kidney disease. 
Even moderate increase in arterial blood pressure shortens life expectancy. 
 Changes in Diet and lifestyle improve blood pressure control and decrease 
the risk of health complications. Drug treatment is necessary in people for whom 
above changes prove insufficient. 
 
 
 
 
 
 
 
  
Table 4: Classification of anti-hypertensives
18
: 
 Diuretics 
 
1. Thiazides: 
 
          2.High ceiling: 
         3.K
+
 sparing: 
Hydrochlorothiazide 
Chlorthalidone 
Furosemide. 
Spironolactone 
 ACE Inhibitors 
 
Captopril 
Enalapril 
 Angiotensin 
( AT 1 receptor ) blockers 
Losartan 
Amlodipine 
 
 β Adrenergic blockers 
 propranolol 
              metroprolol 
 
 
 β + α adrenergic blockers 
 
                           Labetalol 
      Carvedilol 
 α Adrenergic blockers 
 
 
 
Prazosin 
Terazosin 
Dexazosin 
 
 Central sympatholytics 
Phentolamine 
Clonidine 
Methyldopa 
 Vasodilators 
1. Arteriolar: 
 
2. Arteriolar+venous: 
 
Hydralazine, 
Minoxidil, 
Sodium nitropursside 
 
 
 
  
1.10.1 Diuretics
 
Diuretics have been the standard anti-hypertensive drugs though they do not 
reduce BP in normotensives. 
The proposed mechanism of anti-hypertensive action is 
1. Initially, the diuresis reduces plasma and e.c.f volume by 5-15% decreased 
c.o. 
2. Subsequently, compensatory mechanisms operate to almost regain Na 
balance and plasma volume; c.o is restored, but the fall in BP is maintained 
by slowly developing reduction in t.p.r. 
3. The reduction in t.p.r. is mostly probably an indirect consequence of a small 
( 5%) persisting Na and volume deficit. 
1.10.2 Calcium channel blockers
19
: 
Calcium channel blockers work by blocking voltage-gated calcium 
channels (VGCCs) in cardiac muscle and blood vessels. This decreases intracellular 
calcium leading to a reduction in muscle contraction. In blood vessels, a decrease in 
calcium results in less contraction of the vascular smooth muscle and therefore an 
increase in arterial diameter (CCBs do not work on venous smooth muscle), a 
phenomenon called vasodilation. Vasodilation decreases total peripheral resistance, 
while a decrease in cardiac contractility decreases cardiac output. Since blood 
pressure is determined by cardiac output and peripheral resistance, blood pressure 
drops. Calcium channel blockers are especially effective against large vessel 
stiffness, one of the common causes of elevated systolic blood pressure in elderly 
patients. 
1.10.3 Angiotensin II receptor blockers
20
: 
These substances are AT1-receptor antagonists – that is, they block the 
activation of angiotensin II AT1 receptors. Blockage of AT1 receptors directly 
causes vasodilation, reduces secretion of vasopressin, and reduces production and 
secretion of aldosterone, amongst other actions. The combined effect reduces blood 
pressure.  
  
The specific efficacy of each ARB within this class depends upon a 
combination of three pharmacodynamic and pharmacokinetic parameters.  
Angiotensin II receptor blockers are primarily used for the treatment 
of hypertension where the patient is intolerant of ACE inhibitor therapy. They do not 
inhibit the breakdown of bradykinin or other kinins, and are thus only rarely 
associated with the persistent dry cough and/or angioedema that limit ACE inhibitor 
therapy. 
1.11 Combination therapy and Fixed dose combinations
21
: 
Hypertension is a major risk factor for cardiovascular, renal and stroke 
complications. Single-drug therapy remains the preferred way to begin treatment of 
hypertension. The recommendation for first-line therapy for hypertension remains a 
beta blocker or diuretic given in a low dosage, 
  A target blood pressure of less than 140/90 mm Hg is achieved in about 50 
percent of patients, although in many patients this is unable to bring blood pressure 
(BP) to goal levels. It is increasingly appreciated that the elusive goal of a 'normal' 
BP is achieved only if multi-drug therapy is employed. Two or more agents from 
different pharmacologic classes are often needed to achieve adequate blood pressure 
control.  
The options for multi-drug therapy are quite simple: either fixed-dose 
combination therapy or drugs added sequentially one after another to then arrive at 
an effective multi-drug regimen.  
Single-dose combination anti hypertension therapy is an important option 
that combines efficacy of blood pressure reduction and a low side effect profile with 
convenient once-daily dosing to enhance compliance.  
Combination antihypertensive include combined agents from the following 
pharmacologic classes: diuretics and potassium-sparing diuretics, beta blockers and 
diuretics, angiotensin-converting enzyme (ACE) inhibitors and diuretics, 
angiotensin-II antagonists and diuretics, and calcium channel blockers and ACE 
inhibitors. 
 Fixed-dose combination therapy successfully reduces BP because two or 
more drugs, each typically working at a separate site, block different effector 
  
pathways. In addition, the second drug of such two-drug combinations may check 
counter-regulatory system activity triggered by the other. The pattern of adverse 
effects also differs with fixed-dose combination therapy, in part, because fewer 
drugs are generally being given. In addition, one component of a fixed-dose 
combination therapy can effectively counterbalance the tendency of the other to 
produce adverse effects. 
1.12 Rationale for fixed drug combinations
 21, 22
: 
The rationale for using fixed-dose combination therapy is to obtain increased 
blood pressure control by employing two or more antihypertensive agents with 
different modes of action and to enhance compliance by using a single tablet that is 
taken once or twice daily.
 
Using low doses of two different agents can also minimize the clinical and 
metabolic effects that occur with maximal dosages of the individual components of 
the combined tablet. 
 These potential advantages are such that some investigators have 
recommended using combination antihypertensive therapy as initial treatment, 
particularly in patients with target-organ damage or more severe initial levels of 
hypertension. 
For patients requiring 3 drugs, the combination of agents with 
complementary mechanisms of action (i.e., renin-angiotensin- aldosterone system 
blocker, calcium channel blocker, and diuretic) has been recognized as rational and 
effective. 
            Three single-pill triple-drug combinations have recently been approved for 
use in HTN in the United States: valsartan (VAL)/amlodipine (AML) / 
hydrochlorothiazide (HCTZ); olmesartan medoxomil (OM)/AML/HCTZ; and 
aliskiren (ALI)/VAL/HCTZ. Triple-combination regimens have resulted in a greater 
proportion of patients achieving BP control compared with dual combination 
regimens, with significantly lower BP levels 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                     LITERATURE REVIEW 
 
  
  
2.0 Literature review 
 
 Steven G. Chrysant et al23 has performed prespecified subgroup analysis 
from the triple therapy with Olmesartan Medoxomil, Amlodipine, and 
Hydrochlorothiazide in hypertensive patients. Study assessed the efficacy 
and safety of triple-combination treatment (olmesartan medoxomil 
/amlodipine besylate /hydrochlorothiazide) versus the component dual-
combination treatments according to diabetes status (diabetes; non-diabetes). 
In participants with hypertension and diabetes, triple-combination treatment 
led to greater BP reductions and enabled greater proportions of participants 
to reach BP goal versus the dual-combination treatments. Triple-combination 
treatment was well tolerated in both diabetes and non-diabetes subgroups. 
 
 Suzanne oparil et al24 study was to determine whether a triple combination of 
olmesartan medoxomil (OM), amlodipine besylate (AML), and 
hydrochlorothiazide (HCTZ) had a clinically significant benefit compared 
with dual combinations of the individual components in patients with 
moderate to severe hypertension. In these adult patients with moderate to 
severe hypertension, triple combination was associated with significant BP 
reductions compared with dual combinations of the individual components. 
All treatments were generally well tolerated. 
 
 
 Gurudutt nayak et al25 compared the efficacy of triple combination 
(olmesartan 20 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg) vs. 
dual combination (olmesartan 20 mg + amlodipine 5 mg) in patients with 
hypertension and proved that  triple drug combination is more efficacious 
than dual drug combination in the treatment of patients with moderate to 
severe hypertension. 
 
  
 Tsung-Hsien Lin et al26 evaluated the efficacy and safety between a fixed 
dose Combinations(FDC)  and a double dose(DA) for treating mild to 
moderate hypertension after monotherapy failure. They compared the 
systolic blood pressure (SBP)-lowering efficacy of the OA and DA using 
both an office BP and an ambulatory blood pressure monitoring (ABPM) 
device. This study showed that an FDC is more effective than DA in 
reducing SBP for mild to moderate hypertension after the failure of 
monotherapy. 
 
 Giuseppe derosa et al27 purpose of the study was to evaluate a fixed 
olmesartan/amlodipine combination on blood pressure control.  The 
olmesartan/amlodipine combination provided a greater decrease of systolic 
(SBP) and diastolic blood pressures (DBP) compared with amlodipine and 
olmesartan monotherapies. 
 
 
 Aleksandra dukic-ott et al28 main aim of the study was to evaluate modified 
starch as the main excipient for immediate-release pellets containing poorly 
soluble drugs (hydrochlorothiazide and piroxicam). The bioavailability of 
hydrochlorothiazide pellets was not significantly different from fast 
disintegrating immediate-release hydrochlorothiazide tablets. 
 
 Annke frick et al29 described the development of in vitro dissolution tests 
using the paddle and basket apparatus with respect to the 
qualification/validation of the testing procedure. Three immediate release 
products providing different solubility characteristics are evaluated. 
Typically, for immediate release formulations, one limit is specified for the 
dissolution to ensure the release of the active ingredient within the present 
time period. 
 
 
 C. Ferrero et al30 studied the efficiency of croscarmellose sodium in direct 
compression formulation containing a poorly water soluble drug at a high 
  
dose. In their study, they designed an experiment with two variables. They 
are applied pressure and concentration. Tablet properties were evaluated with 
respect to both variables while compression properties evaluated with 
applied pressure. Disintegration response in tablets formulated with a 
disintegrant which is mainly acting by swelling mechanism was optimized. 
 
 Karrar A. Khan31 investigated the effect of variation in compaction force on 
six direct compression tablet matrixes. An instrumented tablet press allowed 
direct measurement of applied and ejection forces. Hardness, apparent tablet 
density, and disintegration times also were determined. The properties 
studied showed varying types of dependence on compaction pressure. A 
direct compression formula was developed and exhibits a decrease in 
disintegration time as compaction force is increased. 
 
 
 Y.X.Bi, H.Sunada et al32 objective is to make rapidly disintegrating tablets 
with sufficient mechanical integrity as well as a pleasant taste. Tablets were 
made by a direct compression method and properties such as porosity, tensile 
strength, and disintegration time were determined. The tensile strength and 
disintegration time were selected as response variables, tablet porosity and 
parameters representing the characteristics of formulation were selected as 
controlling factors, and their relation was determined. Rapidly disintegrating 
tablets with durable structure and desirable taste could be prepared within the 
obtained optimum region. 
 
 G. K. Bolhuis33 formulated two drugs which are used in a low and a medium 
dosage range, respectively with directly compressible excipients and 
compressed into tablets. The results show that with a knowledge of 
properties and interactions of drugs, directly compressible excipients and 
other tablet vehicles, formulations can be composed from which tablets with 
good properties can be prepared. 
 
 
  
 Tiago martinello et al34 purpose of this study was to apply experimental 
design methodology to the development and optimization of tablet 
formulations and manufactured by direct compression.  These results were 
used to generate plots for optimization, mainly for friability. The physical–
chemical data found from the optimized formulation were very close to those 
from the regression analysis, demonstrating that the mixture project is a great 
tool for the research and development of new formulations. 
 
 Markus Wirges et al35 present study demonstrated that Raman spectroscopy 
can be successfully implemented as a process analytical technology tool to 
control and monitor an active-coating process of tablets.  Incorporation of 
an active pharmaceutical ingredient (API) into the coating layer of film-
coated tablets is a method mainly used to formulate combination tablets. In 
the present work, active-coating experiments for osmotic-controlled-release 
oral delivery system (OROS) tablets were performed in a side-vented lab-
scale pan coater. 
 
 
 Gilbert S. Banker36 discussed the recent theory and developments relating to 
the formation and modification of synthetic polymeric films in relation to 
the pharmaceutical uses of such films in dosage form development. 
Fundamental mechanical and physicochemical properties of films as 
affected by plasticization, solvent effects, polymer chemistry, film 
additives, and other factors are considered in relation to film dissolution, 
permeability, and diffusion properties. 
 
 Abu S. Alam†et al37 developed two formulations using polyvinyl 
pyrrolidone for the film coating of tablets by the pan-coating method. The 
addition of ethyl cellulose and shellac eliminated the tackiness sometimes 
associated with polyvinyl pyrrolidone coating due to the hygroscopicity of 
the film former. The film coats increased the resistance of the tablet to 
mechanical stress, did not significantly increase the weight of the tablet, and 
  
were physically acceptable after storage at 2° and 45°. The film coats did 
not interfere with the disintegration and dissolution of the tablet since the 
film coats were rapidly removed from the tablet in water, simulated gastric 
fluid, and simulated intestinal fluid. 
 
 
 Raymond M. Fung† et al38 used a   modified balance to measure the 
adhesive force between the film coating and the tablet surface of 10 
commercial film coated tablets. The adhesiveness or force required to 
remove the film coating from a unit area of tablet surface ranged from 1.06 
to 4.67 × 10
4
Nm
−2
. The method also was useful in studying the influence of 
solvents and humidity on bonding of the film coating to the tablet. 
 
 Louise Ho et al39 demonstrated that  terahertz pulsed imaging (TPI) in 
conjunction with partial least squares regression (PLS ) analysis could be 
employed to assist with film coating process understanding and provide 
predictions on drug dissolution. Understanding the coating unit operation is 
imperative to improve product quality and reduce output risks for coated 
solid dosage forms.  
 
 
 Enosh M wesigwa et al40 studied moisture sorption and permeability 
characteristics of polymer films and their effectiveness to protect a 
hydrolysable drug is assessed. Cast films were prepared, which were also 
applied onto tablet cores formulated with aspirin as a model moisture 
sensitive active ingredient. There was no correlation between 
sorption/permeability characteristics of films and their functionality as 
protective coatings. These results suggest that polymer coatings are not 
sufficiently robust to withstand moisture and do not prevent moisture-
related deterioration of drugs. 
 
 Leon Lachman et al41 described the design and operation of a programmed 
automated tablet coating process. The electronics of the programmer, the 
  
baffle design for the coating pan, and the spray equipment used are 
illustrated and discussed. The advantages and superiority of this process as 
compared with the customary manual coating techniques are presented. 
 
 
 C. Venkata Ram et al42 assessed the safety and efficacy of an 
amlodipine/olmesartan medoxomil (OM)-based titration regimen in patients 
with type 2 diabetes mellitus and hypertension. Drug-related treatment-
emergent adverse events occurred in 19.3% of patients. The most frequent 
events were peripheral edema, dizziness and hypotension.  This 
amlodipine/OM-based titration regimen was well tolerated and effectively 
lowered BP throughout the 24-hour dosing interval in patients with 
hypertension and type 2 diabetes. 
 
 Julie A. Brousil et al43 review describes the mechanism of action, 
pharmacokinetics, adverse-effect profile, drug-interaction potential, 
and dosing of olmesartan medoxomil. The results of relevant clinical 
efficacy and safety trials are also discussed. Olmesartan medoxomil 
has been reported to be an effective agent for the treatment of 
hypertension.  The occurrence of clinically significant drug interactions 
was minimal. Olmesartan medoxomil is an effective angiotensin II-
receptor blocker (ARB) for the treatment of hypertension, with a 
favorable adverse-effect and drug-interaction profile. 
 Steven G Chrysant et al44 purpose of this study was to assess the 
efficacy and safety of the angiotensin II receptor blocker olmesartan 
  
medoxomil in combination with hydrochlorothiazide (HCTZ). 
Olmesartan medoxomil plus HCTZ produced greater reductions in 
both SeDBP and seated systolic blood pressure (SeSBP). 
Olmesartan medoxomil/HCTZ combination therapy produced BP 
reductions of up to 26.8/21.9 mm Hg and was well tolerated. 
 Suzanne Oparil et al45performed a secondary analysis of BP efficacy data 
from a published study that directly compared recommended starting doses 
of four currently marketed ARB to assess combined SBP and DBP goal 
attainment. This analysis showed that the percentage of patients achieving 
the combined SBP/DBP goal rate of <140/90 mm Hg was highest with 
olmesartan medoxomil (32.4%) compared with recommended starting doses 
of other angiotensin II receptor blockers. Optimal ARB monotherapy can 
achieve recommended BP goals in a significant proportion of hypertensive 
patients. However, the majority of hypertensive patients will require 
combination therapy with two or more antihypertensive agents. 
 
 Roberto Fogari46 purpose of the article was to briefly review the evidence 
regarding the efficacy, tolerability, and potential clinical benefits of two 
drugs as single agents and in combination in hypertensive patients with type 
2 DM.  The combination has renoprotective benefits, reducing micro 
albuminuria and stabilizing serum creatinine levels.  There is evidence that 
the combination increases insulin sensitivity, improves coagulation (via an 
increase in tissue plasminogen activity), and reduces left ventricular mass in 
diabetic hypertensive patients. 
 
 
 Ju-Young Kim et al47 aim of the study was to formulate new fixed-dose 
combination tablets (FCTs) by coating an immediate-release (IR) layer on a 
extended-release (ER) core tablet using film coating equipment. The new 
  
FCTs were comprised of the following 3 layers: (a) an ER core tablet, (b) an 
inert mid-layer and (c) an outer IR layer. It was concluded that the inert mid-
layer was necessary to prevent contact between ER core tablet and IR layer 
which retarded the release rate of IR layer. A homogeneous aqueous coating 
suspension was successfully prepared. The coating suspension did not 
contain organic solvent and thus was considered eco-friendly. the active film 
coating method simply required a tableting and coating machine, making it 
more productive and less costly. 
 
 Alan H. Gradman48 addressed the scientific basis of combination therapy, 
presented the pharmacologic rationale for choosing specific drug 
combinations, and review patient selection criteria for initial and secondary 
use. The advantages and disadvantages of single pill (fixed) drug 
combinations, and the implications of recent clinical trials involving specific 
combination strategies were also discussed. 
 
 
 Mahajan HS et al49 prepared rapidly disintegrating oral tablets by 
conventional direct compression method using different superdisintegrants 
like sodium starch glycolate and croscarmellose and diluents used include 
low substituted propyl cellulose and microcrystalline cellulose. Results 
showed that tablet exhibited rapid disintegration in mouth which is the 
characteristic feature desired. 
 
 Marc S Gordan et al50 investigated the effect of aging at various storage 
conditions on the dissolution efficiency of tablets containing three 
superdisintegrants which include croscarmellose, sodium starch glycolate 
and crospovidone using tablets prepared by wet granulation method.  The 
super disintegrants were incorporated via three methods: extra granularly, 
intragranularly, or distributed equally between the two phases. The results 
indicated that aging decreased the dissolution efficiency of super 
disintegrants in wet granulated tablets. Croscarmellose sodium was affected 
  
to a greater extent after storage than crospovidone or sodium starch 
glycolate. Monitoring tablet dimensions showed that there was no substantial 
swelling in tablets after aging at elevated humidity and temperature, except 
for a slight increase in thickness for tablets that contained crospovidone. 
 
 Consuelo Souto et al51study evaluated the utility of including 
superdisintegrants (croscarmellose sodium or sodium starch glycolate) in 
microcrystalline cellulose extrusion–spheronization pellets as a means of 
increasing the dissolution rate of poorly water-soluble drugs. The model drug 
was hydrochlorothiazide, with water or water/ethanol as wetting agent for 
pellet preparation. Neither disintegrant caused disintegration of the pellet in 
drug dissolution medium. Drug dissolution rate was slightly higher in pellets 
prepared with sodium starch glycolate; probably because of this disintegrants 
higher swelling capacity. 
 
 
 Mira Jivraj et al52outlined the various excipients that have been used as 
fillers in direct compression formulations, with particular emphasis on what 
is expected from such excipients in terms of their functionality. It is intended 
that this overview (which is by no means exhaustive) will serve as an ‘aide-
memoire’ to the formulation scientist. 
 
 Lucy S.C. Wan53 studied about influence of disintegrants on disintegration 
time and water uptake. Disintegrants such as sodium starch glycolate 
(NaStglycolate), crospovidone (PVPP) and silicon dioxide (SiO2) play an 
active part in influencing water uptake and disintegration time (DT) of 
sulphanilamide tablets containing methylcellulose (MC) of varying viscosity 
grade as a binder. The DT of tablets containing NaStglycolate decreased with 
an increase in the viscosity of MC due to enhanced water uptake. Tablets 
without MC but only the drug and NaStglycolate were observed to have a 
higher DT and lower water uptake at higher concentrations of the 
  
disintegrant. The choice of excipients, especially binders such as 
methylcellulose, plays a crucial role in influencing disintegrant action. 
 
 
 Larry augsburger L et al54 outlined about the characterization and functions 
of superdisintegrants, the newer one’s which have been developed in the 
recent years. They have been organized into three categories based on their 
chemical structure (such as sodium starch glycolate, crospovidone and 
croscarmellose sodium). It was concluded that adverse effects on fluidity or 
compactibility would be minimized and at levels lower than starch. 
 H V Van Kamp et al55 worked on the improvement of tablet properties by 
superdisintegrants. The crushing strength, disintegration and dissolution of 
tablet was improved when the potato starch in the formulation containing 
lactose as filler and gelatin as binder,  is replaced by much lower 
concentration of an insoluble super disintegrant such as sodium starch 
glycolate or crospovidone. In contrast to potato starch, the position of the 
super disintegrants had hardly any effect on the tablet properties. The 
improved properties of the tablets containing insoluble super disintegrants, 
when compared to tablets with potato starch, are the result of the use of a 
much lower concentration of disintegrant. 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              AIM AND PLAN OF WORK 
 
 
  
3.0 AIM AND OBJECTIVE 
The aim of the present study is to formulate and evaluate a viable triple drug 
fixed dose combination of olmesartan medoximil, amlodipine besylate and 
hydrochlorthiazide film coated tablet for the treatment of hypertension. 
The objective of the study: 
Hypertension is a major risk factor for cardiovascular, renal and stroke 
complications. Since hypertension is a multi factorial condition, its control will 
require the administration of multiple drugs with complimentary mechanisms of 
action.  It is, therefore, important to combine different drugs with complimentary 
mechanisms of action into a single pill. Recent studies have shown that triple-drug 
combinations are very effective, safe and well tolerated by the patients. 
The options for multi-drug therapy are quite simple: either fixed-dose 
combination therapy or drugs added sequentially one after another to then arrive at 
an effective multi-drug regimen.  
The most common combination products comprise a thiazide diuretic and 
a -blocker, thus utilizing the two or more drug classes with the established 
outcome benefits in the treatment of hypertension. The mechanism of action of 
diuretics is retention of sodium by the hypertensive kidney when blood pressure is 
lowered by non-diuretic drugs, thus reducing antihypertensive efficacy. Thiazides 
minimize the sodium retention and so restore efficacy when used in combination. -
blockers lower blood pressure by decreasing cardiac output, alter baroceptor reflex 
sensitivity and block peripheral adrenoceptors. 
Fixed dose of the above three drugs is an effective convenient and well 
tolerated option for treatment of patients with hypertension who require multiple 
anti-hypertensive drugs to achieve blood pressure control. 
The objective of the present study is to develop a stable triple drug 
combination of olmesartan medoximil, amlodipine besylate and hydrochlorthiazide 
for effective and convenient use for treatment of hypertension for patients who 
require multiple anti-hypertensive dosing. 
 
  
4.0 Plan of work 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Preformulation 
Identification and Evaluation of raw materials 
FT-IR studies 
Drug-Excipient compatibility study 
Preparation of granules by wet 
granulation method 
Preparation of a dry blend 
Evaluation of powder blend 
Compression 
Optimized Formulation 
Stability Studies 
Formulation 
Thickness, Hardness, Friability, Drug content, Disintegration Time, In-
vitro dissolution, Uniformity of weight 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                  DRUG PROFILE 
 
  
  
5.0 DRUG PROFILE: 
 
5.1 OLMESARTAN MEDOXIMIL55, 56  :  
Trade name   :             Benicar, Olmetec, WinBP, Erastapex 
Chemical structure: 
 
IUPAC Name : (5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl4-   
                                                       (2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(2H-  
                                                      1,2,3,4    tetrazol-5-yl)phenyl]phenyl}methyl)-  
                                                      1H-imidazole-5- carboxylate 
Molecular formula  :          C29H30N6O6
 
 
Molecular weight  :   558.585 
Melting point   :  175-180
0
C 
Solubility  : Insoluble in water. Sparingly soluble in strong   
                                                     Acid, soluble in strong base, (pH 3 to 9). 
Indications   :  Olmesartan is indicated for the treatment of  
hypertension. It may be used alone or in 
combination with other antihypertensive 
agents.  
Dose    :  20mg once daily 
Loss on drying  :  0.5% max 
Mechanism of action: 
 Olmesartan is a prodrug that works by blocking the binding of angiotensin 
II to the AT1 receptors in vascular muscle; it is therefore independent of angiotensin 
II synthesis pathways, unlike ACE inhibitors. By blocking the binding rather than 
the synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback 
  
on renin secretion. As a result of this blockage, olmesartan 
reduces vasoconstriction and the secretion of aldosterone. This lowers blood 
pressure by producing vasodilation, and decreasing peripheral resistance. 
Interactions: 
Olmesartan may interact with nonprescription products that contain 
stimulants, including diet pills and cold medicines, and potassium supplements, 
including salt substitutes 
Pharmacodynamics: 
Olmesartan medoxomil is an ester prodrug for olmesartan. It is hydrolyzed to 
olmesartan during absorption from the GI tract. Olmesartan is a selective and 
competitive angiotensin II Type 1 (AT1) receptor antagonist and hence it blocks the 
vasoconstrictor and aldosterone-secreting effects of angiotensin II. 
 
Pharmacokinetics: 
Absorption: 
 Orally administered olmesartan medoxomil was rapidly absorbed from the 
gastrointestinal tract and converted during absorption to olmesartan, the 
pharmacologically active metabolite that was subsequently excreted without further 
metabolism. 
Bioavailability :  About 26%.  
Tmax  :  Reached within 1-2 hr. 
 
Distribution and metabolism: 
The medoxomil moiety was released as diacetyl that was rapidly cleared by 
further metabolism and excretion. Peak plasma concentrations of olmesartan 
occurred 1-3 h after administration, after which concentrations decreased quickly. 
The elimination half-life was 10-15 h. Olmesartan medoxomil was not measurable 
in plasma and excreta. The volume of distribution was low, consistent with limited 
extravascular tissue distribution 
Vd  :  17 L; 
Protein binding:  99%. 
 
  
Excretion:  
Excreted as Olmesartan in faeces via the bile (50-65%) and in urine (35-
50%).  
Terminal elimination half-life: About 13 hr. 
 
Olmesartan Medoxomil Adverse Reactions / Side Effects: 
Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, 
nausea, chest pain, bronchitis, cough, pharyngitis, rhinitis, arthritis, back pain, 
fatigue, flu-like symptoms, hypotension, peripheral oedema, haematuria, UTI, 
hyperkalaemia, hypertriglyceridemia, hyperuricaemia, elevated liver enzymes, facial 
edema, angioedema, and rhabdomyolysis, acute renal failure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5.2 AMLODIPINE BESYLATE57, 58: 
Category    : Cardio vascular agent, calcium channel 
Blocker 
Empirical Formula   : C20H25 Cl N2O5 
Molecular Weight   : 408.876 
Structure Formula: 
 
 
 
 
Chemical Name   : 3-Ethyl-5-methyl (±)-2-[(2-aminoethoxy) 
methyl]   
                                                               4-(2-Chlorophenyl)-1,4-dihydro-6-methyl-
3,5                 
                                                               pyridinedicarboxylate, 
Monobenzenesulphonate. 
Appearance    : A white or almost white powder. 
Melting Point    : 195 - 204 C 
Solubility    : Slightly soluble in water, freely soluble in        
                                                        methanol; Sparingly soluble in anhydrous   
  
                                                          ethanol,  slightly soluble in 2-orooanol. 
Indications    : Hypertension and coronary artery disease 
 
Contraindications                          : Breast feeding, Cardiogenic shock, Unstable 
                                                         angina, Aortic stenosis 
 
Interactions: 
 In patients with severe coronary artery disease, amlodipine can increase the 
frequency and severity of angina or actually cause a heart attack on rare 
occasions. 
 Excessive lowering of blood pressure during initiation of amlodipine 
treatment can occur, especially in patients already taking another medication 
for lowering blood pressure. 
Mechanism of action: 
Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist 
or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into 
vascular smooth muscle and cardiac muscle. Experimental data suggest amlodipine 
binds to both dihydropyridine and non dihydropyridine binding sites.  
Amlodipine inhibits calcium ion influx across cell membranes selectively, 
with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. 
Negative inotropic effects can be detected in vitro, but such effects have not been 
seen in intact animals at therapeutic doses.  
Serum calcium concentration is not affected by amlodipine. Within the 
physiologic pH range, amlodipine is an ionized compound (pKa = 8.6), and its 
kinetic interaction with the calcium channel receptor is characterized by a gradual 
rate of association and dissociation with the receptor binding site, resulting in a 
gradual onset of effect. 
Pharmacokinetics and metabolism: 
Absorption: 
  Amlodipine is well absorbed by the oral route with a mean oral 
bioavailability of approximately 60%. Results suggested that absorption of 
amlodipine from capsule was equivalent to that of a solution suggesting that the 
slow transfer of amlodipine into blood is a property of drug, not of the dosage form. 
  
Metabolism and excretion: 
Metabolism of amlodipine is complex and extensive and in common with 
other dihydropyridines oxidation to the pyridine analogue represents a major step. 
Around 5%of a dose was recovered in urine as unchanged drug. Renal elimination is 
the major route of excretion with about 60% of an administered dose recovered in 
urine, largely as inactive pyridine metabolites.  
The major metabolite identified was 2-([4-(2-chlorophenyl)-3-
ethoxycarbonyl-5-methoxycarbonyl-6-methyl- 2-pyridyl] methoxy) acetic acid, and 
this represented 33% of urinary radioactivity. Amlodipine concentrations in plasma 
declined with a mean half-life of 33 h, while elimination of total drug-related 
material from plasma was slower. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5.3 Hydrochlorthiazide59, 60: 
Molecular formula  :  C7H8ClN3O4S2 
Molecular weight  :  297.7 
Molecular structure  : 
 
 
Chemical Name  : 6-Chloro-3,4-dihydro-2H-1,2,4-  
                                                     benzothiadiazine-7-       
                                                     sulphonamide 1,1-dioxide. 
Description     : White to almost white crystalline powder 
Solubility  :  white to almost white colored crystalline            
                                                          powder which is freely soluble in water, soluble   
                                                      in methanol, sparingly soluble in alcohol and   
                                                       slightly soluble in Isopropyl alcohol 
Melting point    :  274 
0
C 
Therapeutic category :   Antihypertensive Agents 
Diuretics 
Sodium Chloride Symporter Inhibitors 
 
 
General Description:  
A thiazide diuretic often considered the prototypical member of this class. It 
reduces the reabsorption of electrolytes from the renal tubules. This results in 
  
increased excretion of water and electrolytes, including sodium, potassium, chloride 
and magnesium. It has been used in the treatment of several disorders including 
edema, hypertension, diabetes insipid us, and hypo parathyroidism.  
Mechanism of Action: 
Thiazide diuretics act in the distal convoluted tubule, where they block Na-
Cl co-transport.  The Na–Cl cotransport takes place on the luminal surface of distal 
convoluted tubules. Thus, to exert their diuretic action; the thiazides must reach the 
luminal fluid. Since the thiazide diuretics are largely bound to plasma proteins and 
therefore are not readily filtered across the glomeruli, access to the luminal fluid is 
accomplished by the proximal tubule organic acid secretory system.  
The drugs then travel along the nephron, presumably being concentrated as 
fluid is abstracted, until they reach their site of inhibitory action in the distal 
convoluted tubule. Especially at higher doses, administration of some of the 
thiazides results in some degree of carbonic anhydrate inhibition. However, at usual 
doses, only chlorothiazide shows any appreciable carbonic anhydride inhibitory 
activity. 
 
Pharmacokinetics 
Hydrochlorothiazide is fairly rapidly absorbed from the gastrointestinal tract. 
It is reported to have a bioavailability of about 65 to 70%. It has been estimated to 
have a plasma half-life of between about 5 and 15 hours and appears to be 
preferentially bound to red blood cells. It is excreted mainly unchanged in the urine. 
Hydrochlorothiazide crosses the placental barrier and is distributed into breast milk. 
 
Absorption and Elimination: 
Orally administered thiazides are rapidly absorbed from the gastrointestinal 
tract and begin to produce dieresis in about 1 hour. Approximately 50% of an oral 
dose is excreted in the urine within 6 hours. 
 These compounds are organic acids and are actively secreted into the 
proximal tubular fluid by the organic acid secretary mechanism. There also appears 
to be an extra renal pathway for their elimination involving the hepatic–biliary acid 
  
secretary system that is particularly important for thiazide elimination when renal 
function is impaired. 
The thiazides have a variable effect on elimination of uric acid, which also is 
secreted by the renal acid secretary mechanism. Administration of thiazide diuretics, 
especially at low doses, may elevate serum uric acid levels and cause gout like 
symptoms. 
 Following large doses, thiazides may compete with uric acid for active reabsorption 
and thereby may promote uric acid elimination rather than impair it. 
 
Adverse Effects 
Thiazides should be used cautiously in the presence of severe renal and 
hepatic disease, since azotemia and coma may result. The most important toxic 
effect associated with this class of diuretics is hypokalemia, which may result in 
muscular and central nervous system symptoms, as well as cardiac sensitization. 
Periodic examination of serum electrolytes for possible imbalances is strongly 
recommended. 
 Appropriate dietary and therapeutic measures for controlling hypokalemia 
are described later in this chapter. The thiazides also possess some diabetogenic 
potential, and although pancreatitis during thiazide therapy has been reported in a 
few cases, the major mechanism contributing to the potential for glucose intolerance 
is not known. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                           EXCIPIENT PROFILE 
 
  
 
6.0 EXCIPIENT PROFILE: 
 
6.1 Croscarmellose sodium61: 
 
Non Proprietary Name  :  USPNF: Croscarmellose sodium. 
 JP: Croscarmellose Sodium 
PhEur: Croscarmellose Sodium 
                                                            USP-NF: Croscarmellose Sodium 
Synonyms   :   Ac-Di-sol; cross-linked carboxy 
methylcellulose   
sodium; Primellose; Solutab; Vivasol. 
 
Structural Formula  : 
 
 
 
 
 
Functional category  :  Tablet and capsule disintegrant. 
 
Chemical name :       Cellulose, carboxy methyl ether, sodium salt,  
   
  
 
Description   :  Croscarmellose sodium occurs as an odorless,   
                                                     white  colored powder. 
 
Molecular weight   :  90000-700000. 
 
PH    :  5.0-7.0. 
 
Solubility   : Insoluble in water. Although croscarmellose    
                                                         sodium rapidly swells to 4-8 times of its original   
                                                     volume on  contact with water. 
Stability, Storage Condition : Croscarmellose sodium is a stable though    
                                           hygroscopic material. Croscarmellose sodium   
                                            should be stored in a well-closed container in a   
                                           cool place. 
Incompatibilities  :          The efficacy of disintegrants, such as   
                                                      Croscarmellose   sodium, may be slightly reduced   
                                                      in tablet  formulations prepared by wet granulation   
                                                     or direct    compression process which contain  
           hygroscopic material such as sorbitol. 
 
Safety    : Croscarmellose sodium is mainly used as a  
     disintegrant in oral pharmaceutical   
                                                      formulations and is generally regarded as an  
                                                      essentially nontoxic and nonirritant material. 
 
 
 
 
 
 
  
6.2 CROSPOVIDONE62: 
 
Nonproprietary Names  : Crospovidone 
PhEur: Crospovidone 
USP-NF: Crospovidone 
Synonyms    : Crospovidonum;Crospopharm;  
      crosslinkedpovidone; E1202; Kollidon 
CL;  
Kollidon CL-M; Polyplasdone XL;  
PolyplasdoneXL-10; PVPP; 
Chemical Name   :  1-Ethenyl-2-
pyrrolidinonehomopolymer 
 CAS Registry Number  : [9003-39-8] 
Empirical Formula   :  (C6H9NO)n>1 000 000 
Molecular Formula   :  A water-insoluble syntheticcrosslinked  
    Homopolymer of N-vinyl-2- 
pyrrolidinone. An exact determination of 
the molecular weight has not been 
established because of the insolubility of 
the material. 
 
Structural Formula   : 
 
 
 
 
  
 
 
Functional Category   : Tablet disintegrant. 
 
 
Applications in Pharmaceutical Formulation or Technology: 
 Crospovidone is a water-insoluble tablet disintegrant and dissolution agent 
used at 2–5% concentration in tablets prepared by direct compression or wet- 
and dry-granulation methods. It rapidly exhibits high capillary activity and 
pronounced hydration capacity, with little tendency to form gels.  
 The particle size of crospovidone strongly influences disintegration of 
analgesic tablets. Larger particles provide a faster disintegration than smaller 
particles.  
 Crospovidone can also be used as a solubility enhancer. With the technique 
of co-evaporation, crospovidone can be used to enhance the solubility of 
poorly soluble drugs. 
  The drug is adsorbed on to crospovidone in the presence of a suitable 
solvent and the solvent is then evaporated. This technique results in faster 
dissolution rate. 
 
Description: 
Crospovidone is a white to creamy-white, finely divided, free flowing, and 
practically tasteless, odorless or nearly odorless, hygroscopic powder. 
 
Stability and Storage Conditions: 
Since crospovidone is hygroscopic, it should be stored in an air tight 
container in a cool, dry place. 
 
Incompatibilities: 
Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, crospovidone may form molecular 
adduct with some materials. 
  
 
Method of Manufacture: 
Acetylene and formaldehyde are reacted in the presence of a highly active 
catalyst to form butynediol, which is hydrogenated to butanediol and then 
cyclodehydrogenated to form butyrolactone.  
Pyrrolidone is produced by reacting butyrolactone with ammonia. This is 
followed by a vinylation reaction in which pyrrolidoneandacetylene are reacted 
under pressure. The monomer vinylpyrrolidone is then polymerized in solution, 
using a catalyst. Crospovidone is prepared by a ‘popcorn polymerization’ process. 
 
 
Safety: 
Crospovidone is used in oral pharmaceutical formulations and is generally regarded 
as a nontoxic and nonirritant material. Short term animal toxicity studies have 
shown no adverse effects associated with crospovidone. 
 
Handling Precautions 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection, gloves, and a dust mask are recommended. 
 
Regulatory Status 
Accepted for use as a food additive in Europe. Included in the FDA. 
 
 
 
 
 
 
 
 
 
 
  
 
6.3 SODIUM STARCH GLYCOLATE63: 
Nonproprietary Names   : BP: Sodium Starch Glycolate 
PhEur: Sodium starch Glycolate 
USPNF:SodiumStarchGlycolate 
 
Synonyms     : Carboxymethyl starch, sodium   
           salt;   
           carboxymethylamylumnatricum;  
Explosol; Explotab; Glycolys;  
Primojel; starch carboxymethyl    
ether, sodium salt; Tablo; 
Vivastar P. 
 
Chemical Name     :  Sodium carboxymethyl starch
  
CAS Registry Number   :  [9063-38-1] 
 
Structural Formula    : 
 
 
 
Functional Category    : Tablet and capsule disintegrant. 
Weight loss on drying%   :  ≤ 0.003 
Appearance     :  White or off white powder, 
odorless, 
  
 moisture absorptive in air 
Particle size     :  100% through 120 mesh sieve 
Solubility     :  insoluble in ethanol, or sulfuric  
ether; dispersing in water or 
becoming viscous colloid 
solution. 
 
 
Applications in Pharmaceutical Formulation or Technology: 
 Sodium starch glycolate is widely used in oral pharmaceuticals as a 
disintegrant in capsule and tablet formulations. 
 It is commonly used in tablets prepared by either direct-compression or wet-
granulation processes.  
 Sodium starch glycolate has also been investigated for use as a suspending 
vehicle. 
 
Description: 
Sodium starch glycolate is a white or almost white free-flowing very 
hygroscopic powder. The PhEur 6.0 states that when examined under a microscope 
it is seen to consist of: granules irregularly shaped, ovoid or pear-shaped, 30–100 
mm in size, or rounded, 10–35 mm in size; compound granules consisting of 2–4 
components occur occasionally; the granules have an eccentric hilum and clearly 
visible concentric striations. 
 
Stability and Storage Conditions: 
Tablets prepared with sodium starch glycolate have good storage properties. 
Sodium starch glycolate is stable although very hygroscopic, and should be stored in 
a well-closed container in order to protect it from wide variations of humidity and 
temperature, which may cause caking. The physical properties of sodium starch 
glycolate remain unchanged for up to 3 years if it is stored at moderate temperatures 
and humidity. 
 
  
 
 Incompatibilities: 
Sodium starch glycolate is incompatible with ascorbic acid. 
 
 
Method of Manufacture: 
Sodium starch glycolate is a substituted derivative of potato starch. 
Typically, commercial products are also cross linked using either sodium 
trimetaphosphate (Types A and B) or dehydration (Type C).   
Starch is carboxy methylated by reacting it with sodium chloro acetate in an 
alkaline, non-aqueous medium, typically denatured ethanol or methanol, followed 
by neutralization with citric acid, acetic acid, or some other acid.  
 
 
Safety: 
Sodium starch glycolate is widely used in oral pharmaceutical formulations 
and is generally regarded as a nontoxic and nonirritant material. However, oral 
ingestion of large quantities may be harmful. 
 
Handling Precautions: 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Sodium starch glycolate may be irritant to the eyes; eye protection 
and gloves are recommended. A dust mask or respirator is recommended for 
processes that generate a large quantity of dust. 
 
Regulatory Acceptance: 
Included in the FDA Inactive Ingredients Database  
 
 
 
 
 
  
6.4 Colloidal Silicon Dioxide64 
 
Nonproprietary Names  :  BP: Colloidal Anhydrous Silica 
                                                     JP: Light Anhydrous Silicic Acid 
   PhEur: Silica, Colloidal Anhydrous 
                                                      USP-NF: Colloidal Silicon Dioxide 
 Synonyms    :Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; 
colloidal  
     silica; fumed silica; fumed silicon dioxide; 
SAS;  
     silica colloidalisanhydrica; silica sol; silicic  
anhydride; silicon dioxide colloidal; silicon 
dioxide  
fumed; synthetic amorphous silica; 
Empirical Formula   : SiO2,   
 Molecular Weight   : 60.08 
Structure    : SiO2 
Functional Category   :Adsorbent; anticaking agent; emulsion  
Stabilizer;glidant; suspending agent; tablet  
disintegrant; thermal stabilizer; viscosity-
increasing agent. 
 
Applications in Pharmaceutical Formulation or Technology: 
 Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and 
food products; 
 Colloidal silicon dioxide is also used to stabilize emulsions and as a 
thixotropic thickening and suspending agent in gels and semisolid 
preparations 
 Colloidal silicon dioxide is also used as a tablet disintegrant and as an 
adsorbent dispersing agent for liquids in powders. 
  Colloidal silicon dioxide is frequently added to suppository formulations 
Description: 
Colloidal silicon dioxide is submicroscopic fumed silica with particle size of 
about 15 nm. It is a light, loose, bluish-white-colored, odorless, tasteless, amorphous 
powder. 
 
  
Incompatibilities: 
Incompatible with diethylstilbestrol preparations 
Method of Manufacture: 
Colloidal silicon dioxide is prepared by the flame hydrolysis of 
chlorosilanes, such as silicon tetrachloride, at 18008C using a hydrogen–oxygen 
flame. Rapid cooling from the molten state during manufacture causes the product to 
remain amorphous. 
 
Stability and Storage Conditions: 
Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water 
without liquefying.  
Colloidal silicon dioxide powder should be stored in a well-closed container. 
 
Safety: 
Colloidal silicon dioxide is widely used in oral and topical pharmaceutical 
products and is generally regarded as an essentially nontoxic and nonirritant 
excipient. However, intraperitoneal and subcutaneous injection may produce local 
tissue reactions and/or granulomas. Colloidal silicon dioxide should therefore not be 
administered parenterally. 
 
 
 
 
 
 
 
 
 
  
6.05 Starch, Sterilizable Maize65   : 
 
Nonproprietary Names  : USP: Absorbable Dusting Powder 
 
Synonyms    : Bio-sorb; double-dressed, white maize 
starch;  
Fluid amid R444P; Keoflo ADP; 
Meritena; modified starch dusting 
powder; Pure-DentB851; starch-
derivative dusting powder; sterilizable 
corn starch. 
 
Chemical Name   :  Sterilizable maize starch 
 
Empirical Formula and Molecular Weight: (C6H10O5)n  
where n = 300–1000.Sterilizable maize starch is a modified corn (maize) starch that 
may also contain up to 2.0% of magnesium oxide. 
 
Structural Formula 
 
 
 
Functional Category   : Diluent; lubricant. 
 
Applications in Pharmaceutical Formulation or Technology 
 Sterilizable maize starch is a chemically or physically modified corn (maize) 
starch that does not gelatinize on exposure to moisture or steam sterilization. 
  
 Sterilizable maize starch is primarily used as a lubricant for examination and 
surgeons’ gloves, although because of safety concerns unlubricated gloves 
are now generally recommended; 
 It is also used as a vehicle for medicated dusting powders. 
 
Description 
Sterilizable maize starch occurs as an odorless, white, free-flowing powder. 
Particles may be rounded or polyhedral in shape. 
 
Stability and Storage Conditions: 
Sterilizable maize starch may be sterilized by autoclaving at 121
0
C for 20 
minutes, by ethylene oxide, or by irradiation. 
 
Method of Manufacture 
Corn starch (maize starch) is physically or chemically modified by treatment 
with either phosphorus oxychloride or epichlorhydrin so that the branched-chain and 
straight-chain starch polymers crosslink. Up to 2.0% of magnesium oxide may also 
be added to the starch. 
 
Safety 
Sterilizable maize starch is primarily used as a lubricant for surgeons’ gloves 
and as a vehicle for topically applied dusting powders. Granulomatous reactions, 
peritonitis and inflammation at operation sites have been attributed to contamination 
with surgical glove powders containing sterilizable maize starch. In addition, glove 
powder may be a risk factor in the development of latex allergy. As a consequence, 
it has been suggested that the use of sterilizable maize starch in latex gloves should 
be prohibited. 
 
Regulatory Status 
Included in the FDA Inactive Ingredients Database 
 
  
6.06 Starch, Pregelatinized66: 
 
Nonproprietary Names  : BP: Pregelatinised Starch 
PhEur: Starch, Pregelatinised 
USP-NF: Pregelatinized Starch 
 
Synonyms    : Amylumpregelificatum; compressible  
Starch C*PharmGel; Instastarch; 
Lycatab C;Lycatab PGS; Merigel; 
National 78-1551; Pharma-Gel; Prejel; 
Sepistab ST200; Spress B820; Starch 
1500 G; Tablitz; Unipure LD;  
      Unipure WG220. 
 
 Chemical Name         :  Pregelatinized starch 
CAS Registry Number  :  [9005-25-8] 
 
Empirical Formula and Molecular Weight: (C6H10O5)n  
where n = 300–1000. 
Structural Formula   : 
 
 
 
 
 
 
  
Functional Category : Tablet and capsule diluent;   
tablet and capsule disintegrant; 
tablet binder. 
 
 
Applications in Pharmaceutical Formulation or Technology: 
 Partially pregelatinized starch is a modified starch used in oral capsule and 
tablet formulations as a binder, diluents and disintegrant. 
 .Both partially and fully pregelatinized starch may also be used in wet 
granulation processes 
 Fully pregelatinized starches can be used to make soft capsules, shells, and 
coatings as well as binders in tablets. 
Description: 
Pregelatinized starch occurs as a moderately coarse to fine, white to off-
white colored powder. It is odorless and has a slight characteristic taste. 
 
Stability and Storage Conditions: 
Pregelatinized starch is a stable but hygroscopic material, which should be 
stored in a well-closed container in a cool, dry place. 
 
Method of Manufacture: 
Food-grade pregelatinized starches are prepared by heating an aqueous slurry 
containing up to 42% w/w of starch at 62–728C. Chemical additives that may be 
included in the slurry are gelatinization aids (salts or bases) and surfactants, added to 
control rehydration or minimize stickiness during drying. After heating, the slurry 
may be spray-dried, roll-dried, extruded, or drum-dried. In the last case, the dried 
material may be processed to produce a desired particle size range. 
 
Safety: 
Pregelatinized starch and starch are widely used in oral solid-dosage 
formulations. Pregelatinized starch is generally regarded as a nontoxic and 
  
nonirritant excipient. However, oral consumption of large amounts of pregelatinized 
starch may be harmful. 
 
Handling Precautions: 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection and a dust mask are recommended. Excessive dust 
generation should be avoided to minimize the risks of explosion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
6.07 Cellulose, Microcrystalline67: 
Nonproprietary Names : BP: Microcrystalline Cellulose 
JP: Microcrystalline Cellulose 
PhEur: Cellulose, Microcrystalline 
USP-NF: Microcrystalline Cellulose 
 
Synonyms   : Avicel PH; Cellets; Celex; cellulose gel;  
hellulosummicrocristallinum; Celphere: Ceolus  
KG; crystalline cellulose; E460; Emcocel; 
Ethispheres; Fibrocel; MCC Sanaq; 
Pharmacel; Tabulose; Vivapur 
 
Chemical Name  :  Cellulose  
CAS Registry Number :  [9004-34-6] 
 
Empirical Formula  : (C6H10O5)n  , Where n - 220. 
Molecular Weight  :  ≈36 000 
Structural Formula  : 
 
 
 
 
 
Functional Category  : Adsorbent; suspending agent; tablet and              
capsule diluent; tablet disintegrant. 
 
  
 
Applications in Pharmaceutical Formulation or Technology: 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and direct-compression processes. 
 In addition to its use as a binder/diluent, microcrystalline cellulose also has 
some lubricant and disintegrant properties that make it useful in tableting. 
Description: 
Microcrystalline cellulose is purified, partially depolymerised cellulose that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous 
particles.  
It is commercially available in different particle sizes and moisture grades 
that have different properties and applications. 
Stability and Storage Conditions: 
Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
Method of Manufacture: 
Microcrystalline cellulose is manufactured by controlled hydrolysis with 
dilute mineral acid solutions of a-cellulose, obtained as a pulp from fibrous plant 
materials.  
Following hydrolysis, the hydrocellulose is purified by filtration and the 
aqueous slurry is spray dried to form dry, porous particles of a broad size 
distribution. 
 Safety: 
Consumption of large quantities of cellulose may have a laxative effect, 
although this is unlikely to be a problem when cellulose is used as an excipient in 
pharmaceutical formulations.  
Handling Precautions: 
  
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Microcrystalline cellulose may be irritant to the eyes. Gloves, eye 
protection, and a dust mask are recommended 
Regulatory Status: 
 GRAS listed. Accepted for use as a food additive in Europe. Included in the 
FDA Inactive Ingredients Database (inhalations;. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
6.08 Magnesium Stearate68: 
 
Nonproprietary Names  : BP: Magnesium Stearate 
JP: Magnesium Stearate 
PhEur: Magnesium Stearate 
USP-NF: Magnesium Stearate 
 
Synonyms    : Dibasic magnesium stearate; 
magnesium  
distearate; magnesiistearas; magnesium  
octadecanoate; octadecanoic acid,  
magnesiumsalt; stearic acid, 
magnesium salt; Synpro 90. 
 
Chemical Name   : Octadecanoic acid magnesium salt  
 
CAS Registry Number  :  [557-04-0] 
 
Empirical Formula   : C36H70MgO4  
 
Molecular Weight   :  591.24 
 
Structural Formula   : [CH3(CH2)16COO]2Mg 
 
Functional Category   : Tablet and capsule lubricant. 
 
Applications in Pharmaceutical Formulation or Technology: 
  Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams. 
 
Description: 
  
Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste. The powder is greasy to the touch and readily adheres to the 
skin. 
 
Incompatibilities: 
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with 
strong oxidizing materials. Magnesium stearate cannot be used in products 
containing aspirin, some vitamins, and most alkaloidal salts. 
 
Method of Manufacture: 
Magnesium stearate is prepared either by the interaction of aqueous solutions 
of magnesium chloride with sodium stearate or by the interaction of magnesium 
oxide, hydroxide, or carbonate with stearic acid at elevated temperatures. 
 
Safety: 
Magnesium stearate is widely used as a pharmaceutical excipient and is 
generally regarded as being nontoxic following oral administration. However, oral 
consumption of large quantities may produce a laxative effect or mucosal irritation. 
No toxicity information is available relating to normal routes of occupational 
exposure.  
 
Handling Precautions: 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection and gloves are recommended. Excessive inhalation 
of magnesium stearate dust may cause upper respiratory tract discomfort, coughing, 
and choking. Magnesium stearate should be handled in a well-ventilated 
environment; a respirator is recommended 
 
Regulatory Acceptance: 
GRAS listed. Accepted as a food additive in the USA and UK. Included in 
the FDA 
  
6.09 Titanium Dioxide69 
 
Nonproprietary Names  : BP: Titanium Dioxide 
JP: Titanium Oxide 
PhEur: Titanium Dioxide 
USP: Titanium Dioxide 
 
Synonyms    : Anatase titanium dioxide; brookite 
titanium  
dioxide; color index number 77891; 
E171; Hombitan FF-Pharma; Kemira 
AFDC; Kronos 1171; pigment white 6; 
Pretiox AV-01-FG; rutile titanium 
dioxide; Tioxide; TiPure; titanic 
anhydride; titaniidioxidum;  
 
Chemical Name   : Dioxotitanium  
 
CAS Registry Number  :  [13463-67-7] 
 
 Empirical Formula   : TiO2  
 
Molecular Weight   :  79.88 
 
Structural Formula   :  TiO2 
 
Functional Category   : Coating agent; opacifier; pigment. 
 
 Applications in Pharmaceutical Formulation or Technology: 
 Titanium dioxide is widely used in confectionery, cosmetics, and foods, in 
the plastics industry, and in topical and oral pharmaceutical formulations as a 
white pigment.  
  
 Owing to its high refractive index, titanium dioxide has light scattering 
properties that may be exploited in its use as a white pigment and opacifier. 
 In pharmaceutical formulations, titanium dioxide is used as a white pigment 
in film-coating suspensions, sugar-coated tablets, and gelatin capsules. 
  Titanium dioxide may also be admixed with other pigments. 
 Titanium dioxide is also used in dermatological preparations and cosmetics, 
such as sunscreens. 
 
Description: 
White, amorphous, odorless, and tasteless non hygroscopic powder. 
Although the average particle size of titanium dioxide powder is less than 1 mm, 
commercial titanium dioxide generally occurs as aggregated particles of 
approximately 100 mm diameter. Titanium dioxide may occur in several different 
crystalline forms: rutile; anatase; and brookite. 
 
Stability and Storage Conditions: 
Titanium dioxide is extremely stable at high temperatures. This is due to the 
strong bond between the tetravalent titanium ion and the bivalent oxygen ions. 
However, titanium dioxide can lose small, unweighable amounts of oxygen by 
interaction with radiant energy.  
This oxygen can easily recombine again as a part of a reversible photo 
chemical reaction, particularly if there is no oxidizable material available. These 
small oxygen losses are important because they can cause significant changes in the 
optical and electrical properties of the pigment. 
Titanium dioxide should be stored in a well-closed container, protected from 
light, in a cool, dry place. 
 
 Incompatibilities: 
Owing to a photocatalytic effect, titanium dioxide may interact with certain 
active substances, e.g. famotidine  
 
 
  
Method of Manufacture: 
Titanium dioxide occurs naturally as the minerals rutile (tetragonal 
structure), anatase (tetragonal structure), and brookite (orthorhombic structure). 
Titanium dioxide may be prepared commercially by either the sulfate or chloride 
process. 
 In the sulfate process, titanium containing ore, such as ilemenite, is digested 
in sulfuric acid. This step is followed by dissolving the sulfates in water, then 
precipitating the hydrous titanium dioxide using hydrolysis. 
 Finally, the product is calcinated at high temperature. In the chloride 
process, the dry ore is chlorinated at high temperature to form titanium tetrachloride, 
which is subsequently oxidized to form titanium dioxide. 
 
Safety: 
Titanium dioxide is widely used in foods and oral and topical pharmaceutical 
formulations. It is generally regarded as an essentially nonirritant and nontoxic 
excipient. 
 
Handling Precautions 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection, gloves, and a dust mask are recommended. 
Titanium dioxide is regarded as a relatively innocuous nuisance dust,(9) that may be 
irritant to the respiratory tract. 
 
 Regulatory Status: 
Accepted as a food additive in Europe. Included in the FDA Inactive 
Ingredients  
 
 
 
 
 
  
6.10 Talc70: 
 
Nonproprietary Names  : BP: Purified Talc 
JP: Talc 
PhEur: Talc 
USP: Talc 
 
Synonyms  : Altalc; E553b; hydrous magnesium  
calcium silicate; hydrous magnesium 
silicate; Imperial; Luzenac Pharma; 
magnesium hydrogen metasilicate; 
MagsilOsmanthus; Magsil Star; 
powdered talc; purified French chalk; 
Purtalc; soapstone; steatite; Superiore; 
talcum. 
 
Chemical Name   : Talc  
 
CAS Registry Number  :  [14807-96-6] 
 
Empirical Formula   : Talc is a purified, hydrated, magnesium  
silicate, approximating to the formula 
Mg6(Si2O5)4(OH)4. It may contain 
small, variable amounts of aluminum 
silicate and iron. 
 
Functional Category   : Anticaking agent; glidant; tablet and  
capsule diluent; tablet and capsule 
lubricant. 
 
 
 
  
Applications in Pharmaceutical Formulation or Technology: 
 Talc was once widely used in oral solid dosage formulations as a lubricant 
and diluents 
 It is widely used as a dissolution retardant in the development of controlled-
release products 
 Talc is also used as a lubricant in tablet  formulations 
 In a novel powder coating for extended-release pellets and as an adsorbant.  
  In topical preparations, talc is used as a dusting powder, although it should 
not be used to dust surgical gloves. 
  Talc is a natural material; it may therefore frequently contain 
microorganisms and should be sterilized when used as a dusting powder. 
  Talc is additionally used to clarify liquids and is also used in cosmetics and 
food products, mainly for its lubricant properties. 
 
Description: 
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free 
from grittiness. 
 
Stability and Storage Conditions: 
Talc is a stable material and may be sterilized by heating at 1608C for not 
less than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma 
irradiation. 
Talc should be stored in a well-closed container in a cool, dry place. 
 
 Incompatibilities: 
Incompatible with quaternary ammonium compounds. 
 
Method of Manufacture: 
Naturally occurring talc is mined and pulverized before being subjected to 
flotation processes to remove various impurities such as asbestos (tremolite); 
carbon; dolomite; iron oxide; and various other magnesium and carbonate minerals. 
  
 Following this process, the talc is finely powdered, treated with dilute 
hydrochloric acid, washed with water, and then dried. The processing variables of 
agglomerated talc strongly influence its physical characteristics. 
 
Safety: 
Talc is not absorbed systemically following oral ingestion and is therefore 
regarded as an essentially nontoxic material. Intranasal or intravenous abuse of 
products containing talc can cause granulomas in body tissues, particularly the lungs 
.  
Contamination of wounds or body cavities with talc may also cause 
granulomas; been proved to be carcinogenic in humans, and asbestos-free grades 
should therefore be used in pharmaceutical products 
 
Handling Precautions: 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Talc is irritant if inhaled and prolonged excessive exposure may 
cause pneumoconiosis 
 
Regulatory Status: 
Accepted for use as a food additive in Europe. Included in the FDA Inactive 
Ingredients Database  
 
Related Substances: 
Bentonite; magnesium aluminum silicate; magnesium silicate; magnesium trisilicate. 
 
 
 
 
 
 
 
  
6.11 Polyethylene Glycol71: 
 
Nonproprietary Names  :  BP: Macrogols 
JP: Macrogol 400 
Macrogol 1500 
Macrogol 4000 
Macrogol 6000 
Macrogol 20000 
PhEur: Macrogols 
USP-NF: Polyethylene Glycol 
 
Synonyms    : Carbowax; Carbowax Sentry; Lipoxol;  
Lutrol E; macrogola; PEG;Pluriol E;  
 polyoxyethylene glycol. 
 
Chemical Name   : a-Hydro-o-hydroxypoly(oxy-1,2- 
ethanediyl)  
 
CAS Registry Number  :  [25322-68-3] 
 
Empirical Formula   : HOCH2(CH2OCH2)mCH2OH where m  
represents the average number of 
oxyethylene groups. 
 
Functional Category   : Ointment base; plasticizer; solvent;  
Suppository base; tablet and capsule  
lubricant. 
 
Applications in Pharmaceutical Formulation or Technology: 
 Polyethylene glycols (PEGs) are widely used in a variety of pharmaceutical 
formulations, including parenteral, topical, ophthalmic, oral, and rectal 
preparations.  
  
 Polyethylene glycol has been used experimentally in biodegradable 
polymeric matrices used in controlled-release systems.(1) 
 Polyethylene glycols are stable, hydrophilic substances that are essentially 
nonirritant to the skin;  
 Solid grades are generally employed in topical ointments, with the 
consistency of the base being adjusted by the addition of liquid grades of 
polyethylene glycol. Mixtures of polyethylene glycols can be used as 
suppository bases. 
 
Description: 
The USP32–NF27 describes polyethylene glycol as being an addition 
polymer of ethylene oxide and water. Polyethylene glycol grades 200–600 are 
liquids; grades 1000 and above are solids at ambient temperatures. 
 Liquid grades (PEG 200–600) occur as clear, colorless or slightly yellow-
colored, viscous liquids. They have a slight but characteristic odor and a bitter, 
slightly burning taste. PEG 600 can occur as a solid at ambient temperatures. 
 
Stability and Storage Conditions: 
Polyethylene glycols are chemically stable in air and in solution, although 
grades with a molecular weight less than 2000 are hygroscopic. Polyethylene glycols 
do not support microbial growth, and they do not become rancid. 
 Polyethylene glycols and aqueous polyethylene glycol solutions can be 
sterilized by autoclaving, filtration, or gamma irradiation. 
 
Method of Manufacture: 
Polyethylene glycol polymers are formed by the reaction of ethylene Method 
of Manufacture Polyethylene glycol polymers are formed by the reaction of ethylene 
oxide and water under pressure in the presence of a catalyst. 
 
Safety: 
Polyethylene glycols are widely used in a variety of pharmaceutical 
formulations. Generally, they are regarded as nontoxic and nonirritant materials. 
  
Adverse reactions to polyethylene glycols have been reported, the greatest toxicity 
being with glycols of low molecular weight. Polyethylene glycols administered 
topically may cause stinging, especially when applied to mucous membranes. 
Hypersensitivity reactions to polyethylene glycols applied topically have also been 
reported, 
 
 
 
Handling Precautions: 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection is recommended. 
 
Regulatory Status: 
Included in the FDA Inactive Ingredients Database (dental preparations; IM 
and IV injections; ophthalmic preparations; oral capsules, solutions, syrups, and 
tablets; rectal, topical, and vaginal preparations). 
 Included in nonparenteral medicines licensed in the UK. Included in the 
Canadian List of Acceptable Non-medicinal 
Ingredients. 
 
Related Substances: 
Polyoxyethylene alkyl ethers; polyethylene oxide; polyoxyethylene sorbitan 
fatty acid esters; polyoxyethylene stearates; suppository bases. 
 
 
 
 
 
 
  
6.12 Methylene chloride72: 
 
Synonyms    : Methylene chloride, methylene 
dichloride,  
Solmethine, Narkotil, Solaesthin, Di-
clo, Freon 30, R-30, DCM, UN 1593, 
MDC 
 
 Chemical Name   :  Dichloromethane 
 
Empirical Formula   :  CH2CL2 
 
Molecular Weight   :  84.93g/mol 
 
Density    :  1.33 g/cm³ 
 
Boiling point    :  39.6 °C 
 
Melting point    :  -96.7 °C 
 
IUPAC ID    :  Dichloromethane 
 
Structural Formula   : 
 
Functional Category   : Solvent 
 
  
Applications in Pharmaceutical Formulation or Technology: 
 Its volatility and ability to dissolve a wide range of organic compounds 
makes it a useful solvent for many chemical processes.  
 It is widely used as a paint stripper and a degreaser. 
 In the food industry, it has been used 
to decaffeinate coffee and tea as well as to prepare extracts 
of hops and other flavorings. 
  Its volatility has led to its use as an aerosol spray propellant and as 
a blowing agent for polyurethane foams. 
Description: 
Methylene chloride is a colorless, volatile liquid with a moderately sweet aroma. 
 
Method of Manufacture: 
DCM is produced by treating either methyl chloride or methane with 
chlorine gas at 400–500 °C. Both methane and methyl chloride undergo a series of 
reactions producing more chlorinated products. 
CH4 + Cl2 → CH3Cl + HCl 
CH3Cl + Cl2 → CH2Cl2 + HCl 
CH2Cl2 + Cl2 → CHCl3 + HCl 
CHCl3 + Cl2 → CCl4 + HCl 
The result of these processes is a mixture of methyl chloride, dichloro 
methane, chloroform, and carbon tetrachloride. These compounds are separated 
by distillation. 
Toxicity: 
  
 DCM is the least toxic chlorohydrocarbons. But because of its 
high volatility, can cause acute inhalation hazard. 
 It is metabolized by the body to carbon monoxide potentially leading 
to carbon monoxide poisoning.  
 Acute exposure by inhalation results in optic neuropathy and hepatitis. 
  Prolonged skin contact cause DCM dissolving some of the fatty 
tissues in skin, resulting in skin irritation or chemical burns. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
6.13 Isopropyl Alcohol73: 
 
 Nonproprietary Names  : BP: Isopropyl Alcohol 
JP: Isopropanol 
PhEur: Isopropyl Alcohol 
USP: Isopropyl Alcohol 
Synonyms    : Alcohol isopropylicus; dimethyl 
carbinol;  
IPA; isopropanol; petrohol; 2-propanol; 
sec-propyl alcohol; rubbing alcohol. 
Chemical Name   :  Propan-2-ol  
 
CAS Registry Number  :  [67-63-0] 
 
Empirical Formula    : C3H8O 
 
Molecular Weight   :  60.1 
 
 Functional Category  : Disinfectant; solvent. 
 
Applications in Pharmaceutical Formulation or Technology: 
 Isopropyl alcohol (propan-2-ol) is used in cosmetics and pharmaceutical 
formulations, primarily as a solvent in topical formulations 
 Although it is used in lotions, the marked degreasing properties of isopropyl 
alcohol may limit its usefulness in preparations used repeatedly 
 Isopropyl alcohol is also used as a solvent both for tablet film-coating and 
for tablet granulation,where the isopropyl alcohol is subsequently removed 
by evaporation. 
  It has also been shown to significantly increase the skin permeability of 
nimesulide from carbomer 934. 
 Isopropyl alcohol has some antimicrobial activity and a 70% v/v aqueous 
solution is used as a topical disinfectant. 
  
 Therapeutically, isopropyl alcohol has been investigated for the treatment of 
postoperative nausea or vomiting. 
 
 
Description 
Isopropyl alcohol is a clear, colorless, mobile, volatile, flammable liquid 
with a characteristic, spirituous odor resembling that of a mixture of ethanol and 
acetone; it has a slightly bitter taste.  
 
Stability and Storage Conditions: 
Isopropyl alcohol should be stored in an airtight container in a cool, dry 
place. 
 
 Incompatibilities: 
Incompatible with oxidizing agents such as hydrogen peroxide and nitric 
acid, which cause decomposition. Isopropyl alcohol may be salted out from aqueous 
mixtures by the addition of sodium chloride, sodium sulfate, and other salts, or by 
the addition of sodium hydroxide. 
 
Method of Manufacture: 
Isopropyl alcohol may be prepared from propylene; by the catalytic 
reduction of acetone, or by fermentation of certain carbohydrates. 
 
 Safety: 
Isopropyl alcohol is widely used in cosmetics and topical pharmaceutical 
formulations. It is readily absorbed from the gastrointestinal tract and may be slowly 
absorbed through intact skin. Prolonged direct exposure of isopropyl alcohol to the 
skin may result in cardiac and neurological deficits. In neonates, isopropyl alcohol 
has been reported to cause chemical burns following topical application. 
 
Handling Precautions: 
  
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Isopropyl alcohol may be irritant to the skin, eyes, and mucous 
membranes upon inhalation. Eye protection and gloves are recommended. Isopropyl 
alcohol should be handled in a well-ventilated environment 
 
 Regulatory Status 
Included in the FDA Inactive Ingredients Database  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
6.14 HPMC74: 
 
Nonproprietary Names   : BP: Hypromellose 
JP: 
Hydroxypropylmethylcellulose 
PhEur: Hypromellosum 
USP: Hypromellose 
 
Synonyms     : Benecel MHPC; E464; 
hydroxypropyl  
Methyl cellulose; HPMC; 
Methocel; methylcellulose 
propylene glycol ether; methyl 
hydroxypropylcellulose;  
Metolose; Tylopur. 
 
Chemical Name     : Cellulose hydroxypropyl 
methyl ether  
 
CAS Registry Number   :  [9004-65-3] 
 
Molecular Weight    : Molecular weight is 
approximately  
10,000 – 1,500,000.  
Structural Formula    : CH3 CH(OH)CH2 
 
Functional Category    : Coating agent; film-former; 
rate- 
controlling polymer for 
sustained release; stabilizing 
agent; suspending agent; tablet 
  
binder; viscosity-increasing 
agent. 
 
Applications in Pharmaceutical Formulation or Technology: 
 Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. 
 In oral products, hypromellose is primarily used as a tablet binder in film-
coating and as a matrix for use in extended-release tablet formulations. 
 Concentrations between 2% and 5% w/w may be used as a binder in either 
wet- or dry-granulation processes.  
 High-viscosity grades may be used to retard the release of drugs from a 
matrix at levels of 10–80% w/w in tablets and capsules.  
 Depending upon the viscosity grade, concentrations of 2–20% w/w are used 
for film-forming solutions to film-coat tablets. Lower-viscosity grades are 
used in aqueous film-coating solutions, while higher-viscosity grades are 
used with organic solvents.  
 Hypromellose at concentrations between 0.45–1.0% w/w may be added as a 
thickening agent to vehicles for eye drops and artificial tear solutions.  
 Hypromellose is also used as an emulsifier, suspending agent, and stabilizing 
agent in topical gels and ointments.  
 As a protective colloid, it can prevent droplets and particles from coalescing 
or agglomerating, thus inhibiting the formation of sediments.  
 Hypromellose is used in the manufacture of capsules, as an adhesive in 
plastic bandages, and as a wetting agent for hard contact lenses. It is also 
widely used in cosmetics and food products. 
 
Description: 
Hypromellose is an odorless and tasteless, white or creamy white fibrous or 
granular powder 
 
Typical Properties: 
Acidity/alkalinity: pH = 5.5–8.0 for a 1% w/w aqueous solution. 
  
Ash: 1.5–3.0%, depending upon the grade and viscosity. 
Auto ignition temperature: 360
0
C 
Density (bulk): 0.341 g/cm
3
 
Density (tapped): 0.557 g/cm
3
 
Density (true) : 1.326 g/cm
3
 
Melting point: browns at 190–2000C; chars at 225–2300C. 
Glass transition temperature is 170–1800C. 
 
Stability and Storage Conditions 
Hypromellose powder is a stable material, although it is hygroscopic after 
drying. Solutions are stable at pH 3–11. Hypromellose undergoes a reversible sol–
gel transformation upon heating and cooling, respectively. Aqueous solutions are 
comparatively enzyme-resistant, providing good viscosity stability during long-term 
storage. Aqueous solutions are liable to microbial spoilage and should be preserved 
with an antimicrobial preservative.  
Aqueous solutions may also be sterilized by autoclaving; the coagulated 
polymer must be redispersed on cooling by shaking. Hypromellose powder should 
be stored in a well-closed container, in a cool, dry place. 
 
Incompatibilities: 
Hypromellose is incompatible with some oxidizing agents. Since it is 
nonionic, hypromellose will not complex with metallic salts or ionic organics to 
form insoluble precipitates. 
 
Method of Manufacture: 
A purified form of cellulose, obtained from cotton linters or wood pulp, is 
reacted with sodium hydroxide solution to produce swollen alkali cellulose that is 
chemically more reactive than untreated cellulose. 
 The alkali cellulose is then treated with chloromethane and propylene oxide 
to produce methyl hydroxypropyl ethers of cellulose. The fibrous reaction product is 
then purified and ground to a fine, uniform powder or granules. 
 
  
Safety: 
Hypromellose is widely used as an excipient in oral and topical 
pharmaceutical formulations. It is also used extensively in cosmetics and food 
products. Hypromellose is generally regarded as a nontoxic and nonirritant. 
 
Handling Precautions 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Hypromellose dust may be irritant to the eyes and eye protection is 
recommended. Excessive dust generation should be avoided to minimize the risks of 
explosion. Hypromellose is combustible. 
 
Regulatory Status 
GRAS listed. Accepted for use as a food additive in Europe. Included in the 
FDA Inactive Ingredients Guide  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS 
 
  
MATERIALS 
Table 6: Materials used in Manufacturing 
 
 
 
List of Materials used in the Study 
 
 
Materials Manufacturer/Suppliers 
 
Olmesartanmedoximil Sequel, Glenmark 
Amlodipine besylate Arch Pharma labs 
Hydrochlorthiazide CPS Pharm labs 
Pregelatinised starch RoquetteFreres,France 
Maize starch Universal starch chem 
Mcc ph 102 Ran Q 
Colloidal silicon dioxide Cabot Sanmar ltd 
Croscarmellose sodium FMC Biopolymer 
Sodium starch glycolate Vasa pharmachem 
crospovidone ISP 
Magnesium stearate  Amishi Drugs & Chemicals Ltd 
HPMC E15 DOW 
Titanium dioxide KRONOS International 
Purified Talc Bharat Pharmaceuticals 
PEG 400 Parchem 
Methylene chloride Gujarat Allealis& Chemicals 
Isopropyl alcohol Lee Changyung Chemicals 
 
 
 
 
 
  
Table 7:  LIST OF EQUIPMENTS 
  
                                             
 
 
 
 
 
 
 
 
 
 
Sl. No Materials  Manufacturers/ Suppliers 
1 Moisture balance Sartorius, Germany  
2 Vibratory sifter Bectochem 
3 Planetary mixer 
(vertical main drive) 
Bectochem 
4 Hexagonal blender Bectochem 
5 Rapid mixer granulator Bectochem 
6 Fluidised bed dryer Bectochem 
7 Tray drier Micro, S.B Panchal& co, India 
8 Multimill Bectochem 
9 Double rotary Compression 
machine(27 station) 
Cadmach, India 
10 dehumidifier Tropical nortec, India 
11 Vernier caliper Mitutoyocorp, Japan  
12 Blister packing machine Labmodule, India 
13 Photo stability &humidity 
chamber  
Thermo labs India Ltd 
  
Table 8: List of Instruments: 
 
Sl. No Instruments Manufacturers/ Suppliers 
1 Electronic weighing balance Shimadzu corporation, Japan 
2 pH Meter Mettler, Toledo, India. 
3 Tap Density apparatus, ETD-1020 Electro lab, India. 
4 Hardness tester Monsanto , India 
5 Friability Test Apparatus, ET-2 Electro lab, India. 
6 Dissolution Apparatus, TDT-08L, Electro lab, India. 
7 Disintegration Apparatus Electro lab, India. 
8 FT-IR Spectrophotometer 8300 Shimadzu corporation, Japan 
9 Differential scanning colorimetry  DSC Q2000 V24.4 build 114  
10 
UV- Visible Spectrophotometer 
(UV-1601) 
Shimadzu corporation, Japan 
11 HPLC with PDA detector Waters HPLC, India. 
12 Refrigerator Whirlpool, India 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 9: List of Reagents 
 
Sl. No 
Reagents/ chemicals 
 
Manufacturers/suppliers 
1 
Potassium dihydrogen ortho 
phosphate AR 
 
Rankem, New Delhi. 
2 
Sodium hydroxide AR 
 
Rankem New Delhi. 
3 
Acetonitrile HPLC 
 
Merck Canada. 
4 
Methanol HPLC 
 
Merck, Canada. 
5 
Sodium dihydrogen ortho 
phosphate AR 
 
Rankem, New Delhi. 
6 
Ortho phosphoric acid AR 
 
Rankem, New Delhi. 
7 
Hydrochloric acid AR 
 
Rankem, New Delhi 
8 
Whatman filter paper 
 
Sartourious 292A, North America. 
9 
0.45 µ filter paper 
 
Millipore, Canada. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
 
  
7.0 EXPERIMENTAL WORK: 
7.1 PREFORMULATION 75: 
Preformulation can be defined as an investigation of physical and chemical 
properties of a drug substance alone and when combined with excipients. The 
overall objective of preformulation testing is to generate information useful to the 
formulator in developing stable and bioavailable dosage forms that can be mass 
produced. The type of information needed will depend on the dosage form to be 
developed. The formal preformulation study should start at the point after biological 
screening, when a decision is made for further development of the compound in 
clinical trials. 
 
7.2 EVALUATION OF RAW MATERIALS: 
7.2.1 Calibration curve: 
Preparation of standard solution for calibration curve of olmesartan 
medoximil
76
:  
           10 mg Standard Olmesartan Medoxomil was accurately weighed and 
transferred to 100 ml volumetric flask and was dissolved properly and diluted up to 
the mark with methanol to produce a stock solution of 100 µg/ml. Appropriate 
amounts of this stock solution were diluted with the same solvent, which yield 
concentrations of 4µg/ml, 6µg/ml, 8µg/ml 10µg/ml, 12µg/ml and 14µg/ml and were 
used for the construction of calibration curve. 
Preparation of standard solution for calibration curve for Amlodipine 
besylate: 
            100mg of Amlodipine besylate was accurately weighed and dissolved in 
25ml of methanolin100ml volumetric flask and the volume was made upto the 
mark using methanol, to make (1000µg/ml) standard stock solution(I).  Then 1ml 
stock solution(I) was taken in another 100ml volumetric  flask and further dilute in 
100ml of methanol to make(10µg/ml) standard stock solution(II), then final 
concentrations were prepared 10,20,30,40 and 50µg/ml with 0.1N HCL. The 
  
absorbance of standard solution was determined using UV/VIS spectrophotometer 
at236nm 
 
Preparation of standard solution for calibration curve of hydrochlorthiazide: 
Weigh accurately 0.025gm of hydrochlorothiazide was  taken in to 100ml of 
standard flask, and added small  volume of methanol and shake well after that make 
up  to the volume with 100 ml (stock solution), from this  solution 10 ml and 
transferred in to 50 ml standard  flask and made up to 50 ml with methanol (which is  
consist of 50 µg/ml used for the analysis), from the  above solution, the sample 
solution was prepared from  five different concentrations using methanol as a 
solvent like 10,20,30,40,and 50µg/ml were used for the  calibration curve analysis 
 
PREPARATION OF BUFFER SOLUTIONS
78
: 
Preparation of 0.1N Hydrochloric Acid (1.2pH): 
8.5 ml of the hydrochloric acid was taken and dissolved in water and made 
upto 1000 ml to get 0.1N hydrochloric acid. 
 
Preparation of Phosphate buffer solution (6.8pH): 
 50 ml of 0.02 M Potassium dihydrogen phosphate was taken in a 200 ml 
volumetric flask. 22.4 ml of 0.02 M sodium hydroxide solution was added and the 
volume was made up to 200 ml using distilled water. 
7.2.2 Raw material analysis for Olmesartan Medoximil 
76
: 
Raw material analysis of Olmesartan Medoximil was done as per IP. 
Identification test was carried out by the Fourier Transform Infra-red 
spectrophotometer (FTIR). The report was shown in fig: 9. 
7.2.3 Raw material analysis for Amlodipine Besylate: 
Raw material analysis of Amlodipine Besylate was done as per IP. 
Identification test was carried out by the Fourier Transform Infra-red 
spectrophotometer (FTIR). The report was shown in fig: 10. 
7.2.4 Raw material analysis for Hydrochlorthiazide: 
Raw material analysis of Hydrochlorthiazide was done as per IP. 
Identification test carried out by the Fourier Transform Infra-red spectrophotometer 
(FTIR). The report was shown in fig: 11. 
 
7.2.5 Drug- Excipient Compatibility Study: 
The drug and the excipients used for the formulation are screened for 
compatibility by physical compatibility study using FT-IR. 
  
7.3 MANUFACTURING PROCESSES: 
 
7.3.1 Flow chart 3: Wet Granulation Process: 
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7.3.2 Flow chart 4: Direct Compression Process: 
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TABLE 10: FORMULATIONS 
 
 
 
 
 
 
 
 
 
  
7.4 EVALUATION OF DRY BLEND76,77: 
7.4.1 Angle of repose: 
   Angle of Repose is defined as the maximum angle possible between the 
surface of a pile of the powder and the horizontal plane.  
The angle of repose was measured by allowing the granules to flow over a 
graph sheet placed on a horizontal surface through a funnel kept at a certain height. 
The height of the heap and circumference of the base of heap was drawn on the 
graph sheet with a pencil and the radius of the circle was measured. 
 The angle of repose was calculated by using the formula given below. 
Angle of 
Repose   
(θ)=Tan1(h/r)            
           where, h = height of pile 
                    r = radius of the base of the pile 
                                    
Table 11:  Angle of repose 
 
 
 
 
 
 
 
 
 
7.4.2 Bulk density determination : 
 Bulk density is the ratio of weight of the powder to the bulk volume 
occupied. Weighed quantity of the powder (W) was taken in a graduated measuring 
cylinder and volume (V0) was measured and bulk density was calculated using the 
formula. 
                         Bulk density = weight of powder/volume of powder 
Angle of Repose Flow property 
  
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very Poor 
  
  
BD =W/V0 g/ml 
 
7.4.3 Tapped density determination : 
Weighed quantity of powder was taken in a graduated cylinder and the 
volume was measured (V0). The graduated cylinder was fixed in the ‘Tapped 
Densiometer’ and tapped for 500, 750 and 1250 times until the difference in the 
volume after consecutive tapings was less than 2%. The final reading was denoted 
by (Vf). The volume of blend was used to calculate the tapped density, Hausner’s 
ratio and Carr’s Index. 
 
Tapped density (TD) = W    g/ml 
            v 
7.4.4 Carr’s index :  
Carr’s index is also known as compressibility.  It  is  indirectly  related  to 
the  relative  flow  rate,  cohesiveness  and  particle  size.  It is simple, fast and 
popular method of predicting powder flow characteristics. 
                      
Table 12: Carr’s index and corresponding flow properties: 
 
 
 
 
 
 
Carr’s Index = (Tapped Density –Bulk Density) x 100 
  Tapped Density  
Carr’s Index (%) Flow 
  
5-15 Excellent 
16-18 Good 
  
18-21 Fair to passable 
23-35 Poor 
33-38 Very poor 
>40 Very very poor 
  
  
7.4.5 Hausner ratio : 
Hausner ratio indicates the flow properties of the powder and measured by 
the ratio of tapped density to bulk density. The relationship between Hauser’s ratio 
and flow property. 
 
Table 13: Hausner  ratio and corresponding flow properties 
 
 
Hausner Ratio Property 
  
0-1.2 Free flowing 
  
1.2-1.6 Cohesive Powder 
  
 
 
Hausner ratio was calculated by using the formula. 
Hausner ratio = tapped density/bulk density 
Hausner ratio = vf / vo 
Where vf = initial volume 
 vo = final volume 
 
7.5 COMPRESSION: 
7.5.1 For granulation process: 
Compress the granules at 200.0 mg average weight in a rotary compression 
machine using 8.00 mm circular concave punch. 
7.5.2 For direct compression process: 
Compress the granules at 170.0 mg average weight in a rotary compression 
machine using 8.00 mm circular concave punch. 
 
 
 
  
Table 14: Film coating formula 
       Ingredients 
        
Quantity 
(mg/tab)          
       HPMC E15 5.1 
   Titanium dioxide 0.75 
            Talc 0.75 
    Isopropyl alcohol 35 
         PEG 400 0.5 
    Methylene chloride 100 
 
FLOW CHART 5: Flow chart for film coating process: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Titanium Dioxide Talc 
 
100
#
 Mesh 
 
Mix 
 
Iso Propyl 
Alcohol 
Methylene Chloride 
Disperse 
 
100
#
 Mesh 
 
Coating over core tablet 
PEG 400 
Constant Stirring 
HPMC E15 
 
  
7.7 EVALUATION OF TABLET
78
: 
7.7.1 General appearance: 
The general appearance of the tablets from each formulation batch was 
observed. The general appearance parameters are shape, color, presence or absence 
of odor and taste were evaluated visually. 
 
7.7.2 Uniformity of Weight: 
Twenty tablets were selected at a random and weighed individually. The 
average weight was calculated. The percentage deviation of tablets was calculated 
and compared with the standard specifications. 
 
Table 15: %deviation for average weight of tablet 
S.No Average weight of a 
tablets 
% deviation 
1 80 mg or less        ±10 
2 80 to 250 mg        ±7.5 
3 above 250 mg        ±5 
 
7.7.3 Thickness: 
The thickness was measured to determine the uniformity of size and shape. 
Thickness of the tablets was measured using vernier caliper. 
 
7.7.4 Hardness:  
Hardness is defined as the force required for breaking a tablet at diametric 
compression test and it is termed as tablet crushing strength. Hardness of the 
prepared formulations was determined using Dr. Schleuniger Pharmatron model 5Y 
tablet tester.  It was expressed in kp. 
 
7.7.5 Friability: 
 Friability of the prepared formulations was determined by using Roche 
friabilator. Pre- weighed sample of tablets was placed in the friability tester, which 
was then operated for 25 revolutions for 4 min, tablets were dedusted and 
  
reweighed. The friability of the tablets was calculated using the formula mentioned 
below. 
F (%) = 
initial weight-final weight 
X100 
initial weight 
 
7.7.6 Disintegration Time: 
 The test is conducted using a specially designed instrument known as 
disintegration apparatus. The apparatus employs a basket of six tubes with a base of 
metal sieve. A tablet is placed in each tube and is held in place.  
 In the six-tube assembly, six tablets are placed and the assembly is 
suspended using a hanger. On the hanger, hanging the six-tube are assembled and 
the assembly is moved in vertical motion in water or a buffer solution at a fixed 
speed of 28- 32 cycles/minute. The time for disintegration of each tablet is recorded. 
7.7.7 ASSAY: 
Chromatographic conditions: 
Buffer solution            :               3.4g KH2PO4 dissolved in 100ml water. P
H 
adjusted to 3.0. 
Mobile phase                :               buffer:acetonitrile 
Column                        :        Inertsil ODS 150×4.6mm, 5µm 
Wave length                 :         264nm 
Injection volume     :        20 µl 
Flow rate                      :        1.0ml/min 
Column temperature      :        30 
0 
c 
Sample holder     :        10
0 
c 
 
Preparation of standard solution: 
  64mg of hydrochlorthiazide, 25mg of equivalent amlodipine besylate and 
100mg of olmesartan medoximil is made upto 200ml with acetonitrile. Further dilute 
10ml of this solution to 50ml with mobile phase. 
Preparation of sample solution: 
 Transfer 5 intact tablets into 200ml volumetric flask, add 10ml of water to 
disperse them and add 150ml of acetonitrile to it. Sonicate to dissolve and make up 
  
the volume with acetonitrile. Further dilute 10ml of this solution to 50ml with 
mobile phase. 
Procedure: 
 Inject 20 µL portion of diluent. Perform replicate injections of standard 
preparation and one injection of each test preparation into the HPLC system ,record 
the chromatograms and measure the peaks response. 
Calculation: 
For Olmesartan Medoximil  
= 
spl 
area 
X 
std 
wt 
X 
10 
X 
200 
X 
50 
X 
Avg 
wt 
X 
std 
purity 
X 
100-
LOD 
X 100 
std 
area 
200 50 
spl 
wt 
10 LC 100 100 
 
For Amlodipine Besylate  
= 
spl 
area 
X 
std 
wt 
X 
10 
X 
200 
X 
50 
X 
Avg 
wt 
X 
purity 
X 
100-
LOD 
X 
408.5 
X 100 
std 
area 
200 50 
spl 
wt 
10 LC 100 100 567.1 
 
For Hydrochlorthiazide: 
= 
spl area 
X 
std wt 
X 
10 
X 
200 
X 
50 
X 
Avg 
wt 
X 
purity 
X 
100-
LOD 
X 100 
std area 200 50 
spl 
wt 
10 LC 100 100 
 
 
 
 
7.7.8 IN-VITRO DISSOLUTION STUDIES: 
DISSOLUTION FOR HYDROCHLORTHIAZIDE AND AMLODIPINE: 
Medium preparation     : 6.8mg of KH2PO4 and 915mg of NaOH is dissolved in                                                                                                                                                                                      
1000ml water and the p
H   
is adjusted to 6.8 with 0.1N HCL or 0 .1N NaOH 
Medium                               :         900ml,    P
H   
6.8, phosphate buffer. 
Apparatus                            :          USP-II (paddle) 
Speed                                  :           50 RPM 
Time                                   :          45min  
  
Temperature                        :         37
0 
c ± 0.5 
0   
c 
Preparation of standard solution:  
 70mg hydrochlorthiazide and 28mg equivalent of 
amlodipine besylate and 110mg of olmesartan medoximil are added to 100ml 
volumetric flask and acetonitrile is added and further volume is made up with 
acetonitrile. Further 2ml of this solution is diluted to 100ml with dissolution 
medium. 
Calculation: 
For Amlodipine Besylate  
= 
spl area 
X 
std wt 
X 
2 
X 
900 
X 
1 
X 
purity 
X 
100-
LOD 
X 
408.5 
X 100 
std 
area 
100 100 1 LC 100 100 567.1 
 
For Hydrochlorthiazide: 
= 
spl area 
X 
std wt 
X 
2 
X 
900 
X 
1 
X 
purity 
X 
100-
LOD X 100 
std area 100 100 1 LC 100 100 
 
 
 
DISSOLUTION MEDIUM FOR OLMESARTAN MEDOXIMIL: 
Medium                                  :      900ml 0.1N HCl 
Apparatus                               :        USP-II Paddle type 
Speed                                     :      50 RPM 
Time                                       :      45min 
Temperature                           :      37
0 
C  ± 0.5 
0   
c 
Preparation of standard solution:  
 110mg of olmesartan medoximil is added to 100ml acetonitrile. Further, 2ml 
of this solution is diluted to 100ml with dissolution medium. 
 
Preparation of buffer: 
 3.4g KH2PO4 dissolved in 100ml water. P
H 
adjusted to 3.0. 
  
For Olmesartan Medoximil:  
= 
spl area 
X 
std wt 
X 
2 
X 
900 
X 
1 
X 
Std 
purity 
X 
100-
LOD 
X 
10
0 std 
area 
100 
10
0 
1 
L
C 
100 100 
Chromatographic conditions for dissolution: 
Mobile phase             :          Buffer:acetonitrile 
Column                     : InertsilODS 150×4.6mm, 5µm 
Wave length                :  264nm 
Injection volume          : 50 µl 
Flow rate                    : 1.0ml/min 
Column temperature    : 30 
0 
c 
Sample holder  : 10
0 
c 
7.8 Stability studies of formulation: 
The stability studies were carried out according to ICH to assess the drug 
formulation stability. Optimized F6 formulation was sealed in aluminium packaging 
laminated with polyethylene. Sample were kept at 25⁰C and 40⁰C and 75% RH for 
1month. At the end of the study period, the formulation was observed for change in 
physical appearance, color, drug content and drug release characteristics. The values 
were showed in the result. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
  
8.  RESULTS AND DISCUSSION: 
8.1 Identification of raw materials: 
Olmesartan medoximil, amlodipine besylate and hydrochlorthiazide were 
subjected to following identification tests and the results shows that they have 
passed all the tests for identification and comply with the limits as per the 
monograph.  
Table 16.0: Identification of raw materials: 
 
 
  
Olmesartan 
 
Amlodipine 
 
Hydrochlorthiazide 
 
 
 
Description 
 
 
white to off-white crystalline 
powder 
 
 
white to off-white 
crystalline powder 
 
 
White to almost white 
crystalline powder 
 
 
 
 
Solubility 
 
Insoluble in water. (sparingly 
soluble in strong acid, soluble 
in strong base, pH 3 to 9) 
 
Slightly soluble in water, 
freely soluble in methanol; 
Sparingly soluble in 
anhydrous ethanol, slightly 
soluble in 2-orooanol. 
 
 
Freely soluble in water, 
soluble in methanol, 
sparingly soluble in 
alcohol and slightly 
soluble in isopropyl 
alcohol 
 
 
Melting 
point 
 
 
 
175-180
0
C 
 
 
 
195 - 204 C 
 
 
 
 
 
274 
0
C 
 
 
 
Loss on 
drying 
 
 
0.5% max 
 
 
NMT 0.5% 
 
 
NMT 1.0% 
  
8.2 Calibration curves:  
8.2.1 For Olmesartan medoximil:  
Calibration curve of Olmesartan Medoximil was prepared.  The 
calibration curve was linear between 2 to 20 µg/ml concentration ranges. The r
2 
and 
slope were found to be 0.998 and 0.042. 
                      Table 17.0: Calibration curve of Olmesartan Medoximil 
Concentration 
(mcg/ml) 
Absorbance 
0 0 
2 0.096 
4 0.177 
6 0.27 
8 0.348 
10 0.421 
 
 
Figure 6. Concentration Vs Absorbance of Olmesartan Medoximil 
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8.2.2 For amlodipine besylate:  
Calibration curve of Amlodipine Besylate was prepared.  The calibration 
curve was linear between 2 to 20 µg/ml concentration ranges. The r
2 
and slope were 
found to be 0.996 and 0.0323. 
 
Table 18.0: Calibration curve of Amlodipine Besylate 
              
 
 
 
 
 
 
 
 
 
Figure 7: Concentration Vs Absorbance of Amlodipine Besylate 
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8.2.3 For Hydrochlorthiazide: 
Calibration curve of Hydrochlorthiazide was prepared.  The calibration 
curve was linear between 2 to 20 µg/ml concentration ranges. The r
2 
and slope were 
found to be 0.989 and 0.012. 
                                 
Table 19.0: Calibration curve of Hydrochlorthiazide 
 
Concentration 
(mcg/ml) 
Absorbance 
0 0 
10 0.156 
20 0.211 
30 0.362 
40 0.487 
50 0.639 
 
 
 
 
 
Figure 8: Concentration Vs Absorbance of Hydrochlorthiazide 
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8.3.1 Raw material analysis of Olmesartan Medoximil: The FT-IR spectrum for 
Olmesartan Medoximil is shown in the figure. It is done as per IP and is used for 
raw material analysis. The spectra show that the raw material obtained is pure. 
 
         Figure 9: FT-IR Spectrum for Olmesartan Medoximil 
 
8.3.2 Raw material analysis for Amlodipine Besylate: 
 The FT-IR spectrum for Amlodipine Besylate is shown in the figure. It is 
done as per IP and is used for raw material analysis. The spectra show that the raw 
material obtained is pure. 
 
                         Figure 10: FT-IR Spectrum for Amlodipine Besylate 
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8.3.2 Raw material analysis for Hydrochlorthiazide: 
 The FT-IR spectrum for Hydrochlorthiazide is shown in the figure. It is 
done as per IP and is used for raw material analysis. The spectra shows that the raw 
material obtained is pure. 
Figure 11: FT-IR Spectrum for Hydrochlorthiazide 
 
8.4 Drug excipient compatibility study: 
8.4.1 Spectrum for Olmesartan medoximil, Amlodipine Besylate and 
Hydrochlorthiazide (1:1:1): 
 
Figure 12: FT-IR Spectrum for 3 drugs (1:1:1) 
 
  
8.4.2 Spectrum for Olmesartan Medoximil and Excipients: 
 
         Figure 13: FT-IR Spectrum for Olmesartan Medoximil and 
excipients 
 
8.4.3 Spectrum for Amlodipine Besylate and Excipients: 
 
 
                   Figure 14: FT-IR Spectrum for Amlodipine Besylate and Excipients 
 
  
8.4.4Spectrum for Hydrochlorthiazide and Excipients: 
 
Figure 15: FT-IR Spectrum for Hydrochlorthiazide and Excipients 
 
8.4.5 Spectrum of Olmesartan Medoximil, Amlodipine Besylate, 
Hydrochlorthiazide and Excipients: 
 
 
Figure 16: FT-IR Spectrum for 3 drugs (1:1:1) and Excipients 
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Interference: The FTIR spectra of the  pure drugs  are shown in the figure 5-12.The 
spectra of pure Amlodipine Besylate, Hydrochlorthiazide, Olmesartan Medoximil 
shows sharp characteristic peaks at 3230.19cm
-1
,1687.41cm
-1
,2971.75cm
-
1
,1116.92cm
-1
(Amlodipine)
 
, 3370.26cm
-1
, 1550.49cm
-1
, 3170.20cm
-1
,
 
1165.53cm
-
1
(Hctz)
 
and 3395.6cm
-1
,  1832.21cm
-1
,1551.81cm
-1
,1289.64cm
-1
 (Olmesartan) 
 
respectively. These peaks are also seen in the spectra of the physical mixtures 
containing the drug and excipients. This indicates there was no interaction between 
the drug and excipients. 
.8.5 Evaluation of Dry Blend: 
                                      Table 20: Angle of Repose 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Evaluation of Angle of Repose 
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s.no.                  
 
Formulations 
 
Angle of repose (θ) 
1.   F-1 27.3 
2.   F-2 28.1 
3.   F-3 39.4 
4.   F-4 35.5 
5.   F-5 31.2 
6.   F-6 24.1 
7.   F-7 27.8 
8.   F-8 28.4 
  
Table 21: Evaluation of granules/blend 
 
 
s.no Formulation 
 
 
 
Bulk 
density 
(g/ml) 
 
Tapped 
density 
(g/ml) 
Hausner’s 
ratio 
Carr’s 
compressability 
 Index % 
1. F-1 0.55 0.621 1.13 11.40 
 
2. 
 
F-2 
 
0.581 0.643 1.11 16.52 
3. 
 
F-3 0.482 0.645 1.33 25.27 
4. 
 
F-4 0.491 0.571 1.16 14.01 
5. 
 
F-5 0.501 0.583 1.16 14.06 
6. 
 
F-6 0.528 0.596 1.13 11.40 
7. 
 
F-7 0.542 0.657 1.21 17.5 
8. 
 
F-8 0.573 0.653 1.13 12.25 
  
 
Figure 18: Evaluation of Bulk Density for various formulations 
 
 
Figure 19: Evaluation of Tapped Density for various formulations 
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Figure 20:   Evaluation of Hausner’s Ratio for various formulations 
 
Figure 21: Evaluation of Carr’s Index for various formulations 
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Inference: 
 Angle of repose was found to be between 270.3`- 4106`. Granules or blend 
possessing the range of less than 25 are considered to have an excellent flow 
property. The results were tabulated in table 17.0. 
 Bulk density was found to be between 0.482-0.581. The results were 
tabulated in table 18.0 
 Tapped density was found to be between 0.571-0.687. The results were 
tabulated in table 19.0 
 Hausner’s Ratio was found to be between 1.11-1.33.lower Hausner’s Ratio 
(<1.25) indicate better flow compared to higher levels(>1.25). The results 
were tabulated in table 20.0 
 Compressibility index was found to be between 11.40-25.27. Index between 
5-15 shows excellent flow property.  The results were tabulated in table 21.0. 
 
 
8.6 Evaluation of tablet: 
 
Table 22.0: Tablet Evaluation 
Formulations Average 
weight 
Uniformity of 
weight 
Thickness Hardness Friabilit
y 
DT 
F1 172.56mg 166- 175 mg 3.01 mm 2.0 kg/cm2 1.14% 18m 45s 
F2 172.20mg 168 – 175mg 3.05 mm 4.0 kg/cm2 0.48% 14 m22s 
F3 168.71mg 167-174mg 3.15mm 3.5 kg/cm2 0.37% 7m 55s 
F4 170.36mg 166-176mg 3.09mm 4.0 kg/cm2 0.22% 7m 30s 
F5 173.21 mg 167 – 175 mg 3.10 mm 4.5 kg/cm2 0.17% 6m 55s’ 
F6 171.58 mg 165 – 173mg 2.98 mm 4.0 kg/cm2 0.22% 3m 31s 
F7 170.69 mg 168 – 175mg 3.03 mm 5.0 kg/cm2 0.13% 5m 45s 
F8 169.71 mg 166 – 173mg 3.06 mm 4.7 kg/cm2 0.19% 5m 20s 
 
 
                
  
 
Figure 22: Evaluation of Average Weight of various formulations 
 
                          
 
Figure 23: Evaluation of Thickness of various formulations 
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Figure 24: Evaluation of Hardness of various formulations 
                         
 
Figure 25:  Evaluation of Friability of various formulations 
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Figure 26: Evaluation of Disintegration time of various formulations 
 
Inference: 
 Eight formulations were prepared and designated as F-1, F-2, F-3, F-4, F-5, 
F-6, F-7 and F-8. 
 Evaluation was carried out and the results were tabulated in table 22. 
 Thickness of all formulations was found to be in range of 2.98-3.10. and 
thickness of all formulations is compared in figure 23. 
 Hardness of all the formulations was found to be in range of 1.5-5 and 
hardness of all formulations is compared in figure 24. 
 Friability of the formulations were observed to be in range of 0.13-1.34% 
and it is compared in figure 25. 
 Uniformity of weight was observed to be within limits mentioned in I.P. 
 Disintegration time was observed to be between 3.2 to 21.22 minutes and the 
DT for all formulations is compared in figure 26. 
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8.7 DRUG CONTENT: 
Table 23: Drug content- olmesartan medoximil 
 
s.no.                  Formulations Drug content 
(%) 
1 F-1 94.34% 
2  F-2 98.81% 
3  F-3 96.23% 
4 F-4 92.87% 
5 F-5 98.12% 
6 F-6 100.86% 
7 F-7 98.95% 
8 F-8 99.02% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 24.0: Drug content- amlodipine besylate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
s.no. Formulations 
 
Drug content 
(%) 
1. F-1 93.56% 
2. F-2 98.23% 
3. F-3 94.12% 
4. F-4 96.12% 
5. F-5 92.34% 
6 F-6 99.22% 
7. F-7 97.78% 
8. F-8 98.54% 
  
Table 25.0: Drug content- hydrochlorthiazide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
s.no. Formulations 
 
Drug content 
(%) 
1. F-1 98.23% 
2. F-2 94.44% 
3. F-3 97.17% 
4. F-4 92.47% 
5. F-5 95.19% 
6. F-6 101.76% 
7. F-7 99.80% 
8. F-8 98.98% 
  
Table 26: In-vitro Dissolution profile 
 
 
 
 
 
 
  
 
Figure 25: In-vitro dissolution profile for formulation F-1 
 
 
 
Figure 26: In-vitro dissolution profile for formulation F-2 
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Figure 27: In-vitro dissolution profile for formulation F-3 
 
 
 
Figure 28: In-vitro dissolution profile for formulation F-4 
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Figure 29: In-vitro dissolution profile for formulation F-5 
 
 
 
Figure 30: In-vitro dissolution profile for formulation F-6 
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Figure 31: In-vitro dissolution profile for formulation F-7 
 
 
 
Figure 32: In-vitro dissolution profile for formulation F-8 
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Figure 33: Chromatogram for standard 
 
 
Figure 34: Chromatogram for sample 
 
 
Figure 35: Dissolution chromatogram for standard 1 
 
  
 
Figure 36: Dissolution for chromatogram for sample 1 
 
 
Figure 37: Chromatogram for dissolution standard 2 
 
 
Figure 38: Chromatogram for dissolution sample 2 
 
  
DISCUSSION: 
The first formulation F-1 has been done with wet granulation method. It shows good 
flow properties but has poor hardness. So the concentration of the binder has been 
increased in the next formulation F-2 to improve hardness. Hardness is improved but 
disintegration time is very high (more than 15min). So, direct compression method 
has been opted in the next formulation F-3. In F-3 formulation also, flow problem is 
observed. Hence, diluent concentration is increased in the next formulation F-4. 
Even then, poor flow property is observed. Diluent concentration is further increased 
in the next formulation F-5 which showed an improved flow property but 
disintegration time is not satisfactory (14min).  Disintegrant concentration is 
increased in the further formulations and various disintegrants are used for 
formulations F-6, F-7, F-8 to compare disintegration property of each and find out 
the optimum disintegrant. Compared to all formulations, F-6 showed enhanced 
disintegration power and drug release rate and possessed good flow property and 
hardness. 
 
 
. 
 
 
 
 
 
 
 
 
 
 
  
Stability studies of formulation: 
 
Table 27: Assay 
 
S.no 
 
 
Temperature 
 
 
Relative 
humidity 
 
Time 
(days) 
 
Olmesarta
n 
Medoxomi
l 
Amlodipine 
Besylate 
Hydrochlorot
-hiazide 
1. 
 
25
 0  
c  ± 2 
0 
c 
 
60% RH 
± 5% RH  
0 100.86 99.22 101.76 
30 99.92 98.34 100.12 
2. 
 
40
 0  
c  ± 2 
0 
c 
 
75% RH 
± 5% RH 
0 100.86 99.22 101.76 
30 98.74 97.51 99.24 
 
Table 28: Dissolution 
 
s.no 
 
 
Temperature 
 
 
Relative 
humidity 
 
Time 
(days) 
 
 
Olmesartan 
Medoximil 
 
Amlodipine 
Besylate 
 
Hydrochlort
-hiazide 
1. 
 
25
 0  
c  ± 2 
0 
c 
 
60% RH 
± 5% RH  
0 99.76 97.12 98.37 
30 98.36 96.61 97.82 
2. 
 
40
 0  
c  ± 2 
0 
c 
 
75% RH 
± 5% RH 
0 99.76 97.12 98.37 
30 97.22 95.12 96.10 
 
 
                                           
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
  
SUMMARY: 
 
 In the present study an attempt was made to prepare triple drug 
combination of Amlodipine besylate, olmesartan medoximil and 
hydrochlorthiazide tablets for the treatment of hypertension. 
 In the formulation developed by trials, F-1 and F-2 were made by wet 
granulation technique; there was a problem with the hardness and later 
with the disintegration time. So to improve the disintegration property, 
direct compression technique was adopted for the remaining trials. 
 In the subsequent formulations F-3, F-4 and F-5, the diluent ratio with 
MCC PH 102 and pregelatinized starch were changed to improve the 
flow property and also the disintegration time.  
 The formulation F-6 containing croscarmellose at its optimum 
concentration of 5% is compared with 5% SSG and 5% crospovidone 
and it was found that croscarmellose was a better disintegrant than the 
other two, as disintegration time and dissolution properties are better 
with the croscarmellose  
 
 The prepared  tablets were evaluated for hardness, friability, weight 
variation, drug content  uniformity, d rug-excipient  interaction,  in  vitro  drug  
release  and  stability studies. 
 Among the various formulations prepared, Formulation F6 with 
croscarmellose sodium (5%) shows minimum disintegration time and improved 
dissolution properties compared to formulation F-1 to F-5. This is because of the 
dual action of wicking and swelling property of disintegrant.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
  
CONCLUSION: 
 
The present research was carried out to develop a novel, stable, triple drug 
combination of amlodipine besylate, olmesartan medoximil and hydrochlorthiazide. 
Combination of Amlodipine Besylate, olmesartan medoximil and hydrochlorthiazide 
are indicated for the successful treatment of hypertension. 
Tablets were formulated by both wet granulation and direct compression 
methods  using olmesartan medoximil, amlodipine besylate, hydrochlorthiazide and 
various excipients which include maize starch, pregelatinised starch, micro 
crystalline cellulose, PVP k30, isopropyl alcohol, MCC PH102, croscarmellose 
sodium, sodium starch glycolate, crospovidone, colloidal silicon dioxide an 
magnesium stearate. Results showed that the wet granulation method was a failure 
because of the disintegration and dissolution properties. Hence other formulations 
adopted a direct compression method and the optimized formulation is found using 
various evaluation properties. The optimized formulation F6 tablets were film 
coated in a conventional coating pan. Formulation characteristics such as content 
uniformity, hardness, friability were evaluated and found to be satisfactory. 
In vitro dissolution studies of tablets were conducted for 30 minutes. 
Samples were analyzed by HPLC. The formulation (F-6) showed acceptable results 
and complied with the internal specifications for weight variation, thickness, 
hardness, friability, drug content and in vitro drug release.  
Accelerated stability profile of tablets was found to be satisfactory. No sign 
of degradation was observed. Hence, it is finally concluded that, triple drug 
combination therapy for hypertension c a n  be considered as one of the promising 
fixed drug dosage form. 
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